user_id,prompt id,pmid_id,selection,annotation,outcome,comparator,intervention,invalid prompt,prompt reason
lidija,82,2875419,Significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).", Weight Gain , detemir , glargine ,0,
lidija,17,2366143,Invalid Prompt,,  cervical Bishop's score  ,  placebo  ,  antibiotic therapy  ,1, No data on cervical Bishop's score after therapy.
lidija,75,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9â??12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7â??9.4; p < .0001) and through 24 weeks follow-up (Weeks 9â??24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6â??7.5; p < .0001).", continuous abstienence at 24 week follow up , placebo , varenicline ,0,
lidija,64,1764008,No significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant., duration of labor stages , epidural analgesia , Meperidine analgesia ,0,
lidija,79,2875419,No significant difference,"27.5 and 25.6% of patients reached the primary outcome with glargine and detemir, respectively, demonstrating the noninferiority of glargine. Improvements in A1C were ?1.46 Â± 1.09% for glargine and ?1.54 Â± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254)", number of patients with A1C <7% , glargine , detemir ,0,
lidija,13,2366143,No significant difference,". No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", neonatal outcomes , antibiotic therapy and tocolysis , tocolysis ,0,
lidija,88,2944158,No significant difference,"IV therapy duration did not differ between groups (P = 0.22),", therapy duration , staff inclination replacement , routine replacement ,0,
lidija,42,2674549,Significantly increased,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively", HAQ-DI score , placebo and methotrexate , 50mg of Golimumab and methotrexate ,0,
lidija,51,524504,Significantly decreased,"there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05)", administration of oxytocin augmentation , dinoprostone , misoprostol ,0,
lidija,43,2674549,Significantly increased,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
lidija,48,524504,Significantly increased,"<td colspan=""6""><hr></td>", number of women who deliver within 12 hours , dinoprostone , misoprostol ,0,
lidija,77,3281242,Cannot tell based on the abstract,,  time to make first quit attempt  ,  placebo  ,  varenicline  ,0,
lidija,77,3281242,Significantly increased,Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074),  time to make first quit attempt  ,  placebo  ,  varenicline  ,0,
lidija,53,524504,No significant difference,"<td colspan=""6""><hr></td>", abnormal fetal heart rate , misoprostol , dinoprostone ,0,
lidija,60,524504,No significant difference,Hyperbilirubinemia 2	9 (11.3%)	5 (6.0%)	NS,  Hyperbilirubinemia  ,  misoprostol  ,  dinoprostone  ,0,
lidija,70,1764008,No significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).,  nausea and vomiting  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
lidija,40,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p?=?0.059) in the golimumab 100 mg plus placebo group,", ACR20  , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
lidija,62,1764008,No significant difference,There was no statistical difference in rates of vacuum-assisted delivery rate., rates of vacuum-assisted delivery rate , epidural analgesia , Meperidine analgesia ,0,
lidija,95,2944158,Significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).",  IVD dwell times  ,  routine replacement  ,  staff inclination replacement  ,0,
lidija,39,2674549,Significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., physical function , methotrexate , golimumab and methotrexate ,0,
lidija,55,524504,Cannot tell based on the abstract,,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
lidija,55,524504,No significant difference,"<td colspan=""6""><hr></td>",  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
lidija,3,3298351,Cannot tell based on the abstract,,  venous ulcer healing  ,  no treatment  ,  compression therapy  ,0,
lidija,3,3298351,Invalid Prompt,,  venous ulcer healing  ,  no treatment  ,  compression therapy  ,1," there is no  ""no treatment"" group"
lidija,15,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", gestational age , placebo , antibiotic therapy ,0,
lidija,26,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
lidija,26,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
lidija,30,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,0,
lidija,30,3233526,Invalid Prompt,,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,1," there is no ""no treatment"" group"
lidija,46,2674549,Cannot tell based on the abstract,, serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
lidija,46,2674549,No significant difference,"serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.", serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
lidija,93,2944158,No significant difference,"5% difference in combined phlebitis and infiltration rates per patient (38% clinically indicated resite, 33% routine resite),",  infiltration  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,81,2875419,No significant difference,Hypoglycemia risk was similar., Hypoglycemia , glargine , detemir ,0,
lidija,34,3233526,Significantly increased,There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks., ferritin levels at week 28 , twice weekly single iron tablet , daily single iron tablets ,0,
lidija,27,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
lidija,27,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
lidija,90,2944158,Significantly increased,with significantly higher hospital costs per patient (P < 0.001)., cost per patient , staff inclination replacement , routine replacement ,0,
lidija,18,2366143,Invalid Prompt,,  white blood cell count  ,  placebo  ,  antibiotic therapy  ,1, there is no data on white blood cells count
lidija,23,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , daily single iron tablets , weekly supplements of two iron tablets ,0,
lidija,16,2366143,Invalid Prompt,,  frequency of contractions  ,  placebo  ,  antibiotic therapy  ,1, there is no data on frequency of contractions
lidija,56,524504,Cannot tell based on the abstract,,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
lidija,56,524504,No significant difference,"<td colspan=""6""><hr></td>",  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
lidija,54,524504,Significantly increased,uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group,  uterine tachysystole  ,  dinoprostone  ,  misoprostol  ,0,
lidija,67,1764008,Significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 Â± 3 vs. meperidine, 6 Â± 4; P < 0.0001) and second stage (epidural, 4 Â± 3 vs. meperidine, 8 Â± 2; P < 0.0001) of labor.",  pain levels during first stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
lidija,37,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L)", ferritin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
lidija,85,2944158,No significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).", IVD comlication rates , staff inclination replacement , routine replacement ,0,
lidija,76,3281242,Cannot tell based on the abstract,,  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
lidija,76,3281242,No significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).",  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
lidija,41,2674549,No significant difference,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p?=?0.240),", Median HAQ-DI score , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
lidija,89,2944158,Significantly increased,A total of 22% of patients in the routinely replaced group had three or more IVDs compared with 9% in the clinical indication group.,  frequency of replacements  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,49,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 24 hours , dinoprostone , misoprostol ,0,
lidija,58,524504,No significant difference,Neonatal resuscitation	9 (11.3%)	9 (10.8%),  Neonatal resuscitation  ,  misoprostol  ,  dinoprostone  ,0,
lidija,96,2858204,Significantly increased,complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group, frequency of healed index ucler after 1 year , placebo , HBOT  ,0,
lidija,80,2875419,Significantly increased,more detemir-treated patients reaching A1C <6.5% (P = 0.017)., number of patients with A1C <6.5% , glargine , detemir ,0,
lidija,91,2944158,No significant difference,"There remained no effect when events were expressed per patient or per 1,000 IVD days.",  IVD complications per person  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,44,2674549,Cannot tell based on the abstract,,  serious adverse events  ,  placebo and methotrexate  ,  100mg of Golimumab and methotrexate  ,0,
lidija,44,2674549,Significantly increased,"Serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients, respectively.,The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3;,<td align=""left"" colspan=""1"" rowspan=""1"">Serious adverse events</td><td align=""char"" colspan=""1"" rowspan=""1"">5 (3.7%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.09 (0.03 to 0.21)</td><td align=""char"" colspan=""1"" rowspan=""1"">8 (6.0%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.11 (0.06 to 0.19)</td><td align=""char"" colspan=""1"" rowspan=""1"">9 (4.2%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.08 (0.04 to 0.14)</td><td align=""char"" colspan=""1"" rowspan=""1"">13 (12.4%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.18 (0.10 to 0.30)</td>",  serious adverse events  ,  placebo and methotrexate  ,  100mg of Golimumab and methotrexate  ,0,
lidija,22,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups, birth outcome , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
lidija,92,2944158,No significant difference,"Phlebitis, n (%)	12 (7%)	18 (10%)",  phlebitis  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,65,1764008,No significant difference,Oxytocin augmentation After initiation of Analgesia	197(100)	192(96)	NS,  oxytocin augmentation  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
lidija,4,3298351,No significant difference,complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system.,  venous ulcer healing  ,  two-layer bandage  ,  four-layer bandage  ,0,
lidija,74,3281242,Significantly increased,Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9â??12: 53.1% vs. 19.3%;, continuous abstienence at week 12 , placebo , varenicline ,0,
lidija,97,2858204,No significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively",  hypoglycemia occuring after treatment  ,  placebo  ,  HBOT   ,0,
lidija,86,2944158,No significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).", time until first complication , staff inclination replacement , routine replacement ,0,
lidija,71,1764008,No significant difference,"here was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups. Differences in the duration of the active-first and the second stages of labor were not statistically significant. The number of newborns with 1-min and 5-min Apgar scores less than 7, did not differ significantly between both analgesia groups", obstetric outcome , epidural analgesia , Meperidine analgesia ,0,
lidija,20,3233526,No significant difference,"Twice-weekly supplementation is as effective as daily supplementation, and may represent an acceptable compromise in iron supplementation regimens for nonanemic pregnant women.", pregnancy , daily single iron tablets , weekly supplements of two iron tablets ,0,
lidija,83,2875419,Significantly decreased,"nsulin doses, however, were significantly lower for glargine: 43.5 Â± 29.0 versus 76.5 Â± 50.5 units/day",  frequency of insulin doses  ,  detemir  ,  glargine  ,0,
lidija,2,3298351,No significant difference,"The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system â?? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings â?? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , compression stocking , four-layer bandage ,0,
lidija,66,1764008,Cannot tell based on the abstract,,  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
lidija,66,1764008,No significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 Â± 1.2 vs. intravenous meperidine, 9 Â± 1.3; P = 0.09).",  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
lidija,29,3233526,Cannot tell based on the abstract,, hemoglobin levels at week 28 , no treatment , daily single iron tablets ,0,
lidija,29,3233526,Invalid Prompt,, hemoglobin levels at week 28 , no treatment , daily single iron tablets ,1," there is no ""no treatment"" group"
lidija,45,2674549,Cannot tell based on the abstract,,  serious adverse events  ,  Golimumab 100 mg and placebo  ,  100mg of Golimumab and methotrexate  ,0,
lidija,45,2674549,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"">Serious adverse events</td><td align=""char"" colspan=""1"" rowspan=""1"">5 (3.7%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.09 (0.03 to 0.21)</td><td align=""char"" colspan=""1"" rowspan=""1"">8 (6.0%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.11 (0.06 to 0.19)</td><td align=""char"" colspan=""1"" rowspan=""1"">9 (4.2%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.08 (0.04 to 0.14)</td><td align=""char"" colspan=""1"" rowspan=""1"">13 (12.4%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.18 (0.10 to 0.30)</td>,The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3;",  serious adverse events  ,  Golimumab 100 mg and placebo  ,  100mg of Golimumab and methotrexate  ,0,
lidija,73,1764008,No significant difference,"The number of newborns with 1-min and 5-min Apgar scores less than 7, did not differ significantly between both analgesia groups.", neonatal outcome , epidural analgesia , Meperidine analgesia ,0,
lidija,10,3298351,Cannot tell based on the abstract,, higher percentage of healed area , Compression stocking , layer compression ,0,
lidija,10,3298351,No significant difference,"The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system â?? on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings â?? on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", higher percentage of healed area , Compression stocking , layer compression ,0,
lidija,31,3233526,No significant difference,"here was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 ?g/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
lidija,9,3298351,Significantly increased,greater dynamics of healing was observed in patients treated with the four-layer Profore system â?? the average loss of area during the whole 12-week observation period was 0.63 cm2/per week.,  faster healing dynamics  ,  Compression stocking  ,  layer compression  ,0,
lidija,63,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", c-section , epidural analgesia , Meperidine analgesia ,0,
lidija,38,2674549,Significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA, symptoms of RA , methotrexate , golimumab and methotrexate ,0,
lidija,84,2875419,Cannot tell based on the abstract,,  drop-out rate  ,  glargine  ,  detemir  ,0,
lidija,84,2875419,Significantly increased,"our study confirms the higher weight gain, lower daily insulin doses, and fewer drop-outs (because of adverse events) for glargine versus detemir,",  drop-out rate  ,  glargine  ,  detemir  ,0,
lidija,94,2944158,No significant difference,"Occlusion, n (%)	5 (3%)	4 (2%)",  occlusion  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,87,2944158,No significant difference,No cases of local infection or IVD-related bloodstream infection occurred in either group.,  infections  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,7,3298351,No significant difference,Initial CEAP score (x Â± SD)	11.9 Â±1.12	11.2 Â±1.3	12.6 Â±1.4,  CEAP scores  ,  compression stocking  ,  two-layer bandage  ,0,
lidija,5,3298351,Significantly increased,Initial CEAP score (x Â± SD)	11.9 Â±1.12	11.2 Â±1.3	12.6 Â±1.4,  CEAP scores  ,  two-layer bandage  ,  four-layer bandage  ,0,
lidija,33,3233526,Significantly increased,. There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks, ferritin levels at week 28 , weekly supplements of two iron tablets , daily single iron tablets ,0,
lidija,28,3233526,Cannot tell based on the abstract,,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
lidija,28,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
lidija,19,3233526,No significant difference,the twice-weekly regime has shown equal effectiveness as a daily supplementation regimen with respect to maintaining safe hemoglobin and ferritin levels throughout pregnancy.,  pregnancy  ,  weekly supplements of two iron tablets  ,  twice weekly single iron tablet  ,0,
lidija,12,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", birth weight , antibiotic therapy and tocolysis , tocolysis ,0,
lidija,24,3233526,No significant difference,"An overall comparison of average birth parameters for the three treatment groups is summarized in Table 3. Infants born to women who were assigned to the different treatment groups showed no significant difference in average birth weight (P = 0.521). The difference in pregnancy termination week was insignificant across the randomization groups (P = 0.13), as was the incidence of cesarean section births, preterm delivery, and low birth weight across the groups (P = 0.31, 0.25, and 0.33, respectively). Two babies (one in Group A and one in Group C) were of low birth weight, and eight babies (Group A, n = 4; Group B, n = 3; Group C, n = 1) were delivered preterm.",  birth outcome  ,  twice weekly single iron tablet  ,  daily single iron tablets  ,0,
lidija,35,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant", ferritin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
lidija,11,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", interval to delivery , antibiotic therapy and tocolysis , tocolysis ,0,
lidija,72,1764008,No significant difference,There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, obstetric intervention , epidural analgesia , Meperidine analgesia ,0,
lidija,36,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant", ferritin levels at week 38 , daily single iron tablets , weekly supplements of two iron tablets ,0,
lidija,59,524504,No significant difference,Cord blood pH (arterial)1	7.28 Â± 0.05	7.27 Â± 0.05	NS,  Core blood pH  ,  misoprostol  ,  dinoprostone  ,0,
lidija,57,524504,Cannot tell based on the abstract,,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
lidija,57,524504,No significant difference,Perinatal death 0 1(1.2%) NS ,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
lidija,61,524504,No significant difference,Birth trauma 3	0	2 (2.5%)	NS,  Birth trauma  ,  misoprostol  ,  dinoprostone  ,0,
lidija,98,2858204,Significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).",  downsizing of ucler area 2 weeks after treatment  ,  placebo  ,  HBOT   ,0,
lidija,32,3233526,No significant difference,"At 38 weeks, the mean hemoglobin level in Group B was significantly lower than in Group A and Group C (P = 0.018), but the difference was of no clinical significance.",  hemoglobin levels at week 38  ,  twice weekly single iron tablet  ,  daily single iron tablets  ,0,
lidija,69,1764008,Significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001),  hypotension  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
lidija,14,2366143,Significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group., infection , placebo , antibiotic therapy ,0,
lidija,21,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , twice weekly single iron tablet , daily single iron tablets ,0,
lidija,8,3298351,Cannot tell based on the abstract,, venous ulcer healing , Profore compression , ProGuide system ,0,
lidija,8,3298351,No significant difference,"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , Profore compression , ProGuide system ,0,
lidija,52,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol", Caesarean section rate , misoprostol , dinoprostone ,0,
lidija,78,2875419,No significant difference,Improvements in A1C were ?1.46 Â± 1.09% for glargine and ?1.54 Â± 1.11% for detemir (P = 0.149), improved A1C , glargine , detemir ,0,
lidija,50,524504,Significantly increased,". With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05)", spontaneous rupture of membranes , dinoprostone , misoprostol ,0,
lidija,68,1764008,Cannot tell based on the abstract,,  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
lidija,68,1764008,Significantly increased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 Â± 3 vs. meperidine, 6 Â± 4; P < 0.0001) and second stage (epidural, 4 Â± 3 vs. meperidine, 8 Â± 2; P < 0.0001) of labor.",  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
lidija,6,3298351,No significant difference,11.9 Â±1.12	11.2 Â±1.3	12.6 Â±1.4	p > 0.05,  CEAP scores  ,  compression stocking  ,  four-layer bandage  ,0,
lidija,25,3233526,Cannot tell based on the abstract,,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
lidija,25,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
lidija,47,524504,Significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).", induction-delivery interval , dinoprostone , misoprostol ,0,
lidija,191,2517154,Cannot tell based on the abstract,, Dysmenorrhea scores , Placebo , Infliximab ,0,
lidija,191,2517154,No significant difference,Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001)., Dysmenorrhea scores , Placebo , Infliximab ,0,
lidija,159,2708184,Cannot tell based on the abstract,,  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
lidija,159,2708184,No significant difference,"<td colspan=""8""><hr></td>",  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
lidija,128,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,128,2871176,Significantly increased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,114,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0%  , Liraglutide (1.2 mg) plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,114,2871176,No significant difference,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (?1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (?0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride", Patients reaching HbA1c goals less than 7.0%  , Liraglutide (1.2 mg) plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,211,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,211,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,179,2864284,Cannot tell based on the abstract,,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,179,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,132,2871176,Cannot tell based on the abstract,,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
lidija,132,2871176,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1"">Liraglutide 1.2 mg</td><td align=""center"" colspan=""1"" rowspan=""1"">0.45 Â± 0.31</td><td align=""center"" colspan=""1"" rowspan=""1"">0.33 Â± 0.20</td><td align=""center"" colspan=""1"" rowspan=""1"">?0.10 (?0.16; ?0.05)<xref ref-type=""table-fn"" rid=""tf2-2"">â? </xref></td><td align=""center"" colspan=""1"" rowspan=""1"">?0.07 (?0.11; ?0.02)<xref ref-type=""table-fn"" rid=""tf2-1"">*</xref></td>,P < 0.0001.",  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
lidija,134,2871176,Cannot tell based on the abstract,,  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
lidija,134,2871176,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1"">Liraglutide 1.8 mg</td><td align=""center"" colspan=""1"" rowspan=""1"">0.48 Â± 0.33</td><td align=""center"" colspan=""1"" rowspan=""1"">0.36 Â± 0.20</td><td align=""center"" colspan=""1"" rowspan=""1"">?0.09 (?0.15; ?0.03)<xref ref-type=""table-fn"" rid=""tf2-1"">*</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">?0.05 (?0.10; ?0.01)<xref ref-type=""table-fn"" rid=""tf2-1"">*</xref></td>,P? 0.05;",  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
lidija,103,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,143,2871176,Cannot tell based on the abstract,,  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
lidija,143,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â??2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â??2.3 mmHg).",  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
lidija,188,2517154,Cannot tell based on the abstract,,  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,0,
lidija,188,2517154,Invalid Prompt,,  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,1, there is no data on pathology examination
lidija,163,2708184,Cannot tell based on the abstract,,  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
lidija,163,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
lidija,189,2517154,Cannot tell based on the abstract,, Pain estimates after surgery , Placebo , Infliximab ,0,
lidija,189,2517154,No significant difference,"After surgery, pain scores decreased in both groups to less than 20% of the initial value.", Pain estimates after surgery , Placebo , Infliximab ,0,
lidija,176,2864284,Cannot tell based on the abstract,,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,176,2864284,Significantly increased,<td></td><td></td><td></td><td></td>,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,178,2864284,Cannot tell based on the abstract,,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,178,2864284,No significant difference,<td></td><td></td><td></td><td></td>,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,147,2871176,Cannot tell based on the abstract,,  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
lidija,147,2871176,No significant difference,"<td align=""left"">?Group A</td><td align=""left"">60 Â± 12</td><td align=""left"">76 Â± 14</td><td align=""left"">78 Â± 13</td><td align=""left"">84 Â± 18</td><td align=""left"">84 Â± 7</td><td align=""left"">92 Â± 10</td><td></td>",  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
lidija,197,3187863,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11â??1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16â??2.13).",  Pain relief: Acupuncture  , Normal unit & Special unit ,  Midwife-led unit  ,0,
lidija,192,1852268,No significant difference,"At the primary efficacy endpoint 2â??4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillinâ??tazobactam were cured (95% confidence interval for the difference, adjusting for strata, â??4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillinâ??tazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
lidija,204,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , high Ab group ,0,
lidija,204,4106715,Significantly increased,"3â??AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â??6.37).", Prolonged abstinence from smoking rates to 12 months , placebo , high Ab group ,0,
lidija,164,2708184,Cannot tell based on the abstract,,  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
lidija,164,2708184,Significantly decreased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
lidija,121,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,121,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,160,2708184,Cannot tell based on the abstract,, Late Life Function and Disability Instrument , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,160,2708184,No significant difference,"<td colspan=""8""><hr></td>", Late Life Function and Disability Instrument , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,201,2688140,No significant difference,"The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups."," The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS ", table-based PEEP (control) group , Decremental PEEP titration group ,0,
lidija,130,2871176,Cannot tell based on the abstract,, Weight gain , Liraglutide plus glimepiride , Rosiglitazone plus glimepiride ,0,
lidija,130,2871176,Significantly increased,"Changes in body weight with liraglutide 1.8 mg (?0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (?0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg)", Weight gain , Liraglutide plus glimepiride , Rosiglitazone plus glimepiride ,0,
lidija,135,2871176,Cannot tell based on the abstract,, HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,135,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),", HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,208,2206488,Significantly decreased,"A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found"," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,169,2864284,Cannot tell based on the abstract,, Parasite clearance at day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,169,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Parasite clearance at day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,137,2871176,Cannot tell based on the abstract,, HOMA-B , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,137,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01)", HOMA-B , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,209,2206488,Cannot tell based on the abstract,, Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,209,2206488,Significantly increased,"<td align=""left"">?Group A</td><td align=""left"">2.3 Â± 0.45</td><td align=""left"">2.4 Â± 0.39</td><td align=""left"">2.4 Â± 0.63</td><td align=""left"">2.7 Â± 0.63</td><td align=""left"">3.0 Â± 0.98</td><td align=""left"">3.4 Â± 0.94</td><td></td>", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,120,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,120,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,100,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,100,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (?0.4%)", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,154,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,154,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,205,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
lidija,205,4106715,No significant difference,"As a secondary outcome, continuous abstinence rate (CAR) to 52 weeks were evaluated from weeks 19 to 52 and were significantly higher for the high Ab group vs. placebo (19.7% vs. 10.0%, p=0.044, OR=2.64, 95% CI, 1.03â??6.79) with no significant difference between the low Ab group and placebo", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
lidija,156,2708184,Cannot tell based on the abstract,, Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
lidija,156,2708184,Significantly decreased,"<td colspan=""8""><hr></td>", Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
lidija,198,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage,", Postpartum haemorrhage , Normal unit & Special unit , Midwife-led unit ,0,
lidija,112,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,112,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,212,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,177,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Cure rate at day 28 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,155,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
lidija,155,2708184,Significantly increased,"<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
lidija,184,2517154,Cannot tell based on the abstract,, Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
lidija,184,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis", Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
lidija,117,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,117,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,119,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,119,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001), ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,166,3001156,Cannot tell based on the abstract,, Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,166,3001156,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">Â Â Chi-square trend test for care from Kumudini Hospital, comparison Group</td><td align=""left"" colspan=""6"" rowspan=""1"" valign=""top"">Chi-square for linear trend=4.47, df=1, p=0.035</td>", Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,123,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,199,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes."," Neonatal outcomes were evaluated by Apgar score <7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth ", Normal unit & Special unit , Midwife-led unit ,0,
lidija,207,4106715,Significantly increased,"3â??AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â??6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
lidija,99,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,99,2871176,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (?1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%)", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,206,4106715,No significant difference,"The difference in the median reduction in cigarette consumption, following the TQD, between the high Ab non-abstainers and placebo non-abstainers was on average 4.6 cigarettes per day. Similarly, cotinine geometric mean concentrations (GMCs) were 19.0% lower on average following the target quit date in the high Ab non-abstainers as compared to placebo non-abstainers.,No significant compensatory smoking in response to the presence of anti-nicotine antibodies, as determined by the number of cigarettes smoked per day, carbon monoxide levels or cotinine levels, was observed in this study.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19â??52) with high Ab levels ,0,
lidija,172,2864284,Cannot tell based on the abstract,, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,172,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,107,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,107,2871176,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (?1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (?0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,195,3187863,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59â??0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56â??0.86)", Oxytocin infusion for augmentation of labour , Normal unit & Special unit , Midwife-led unit ,0,
lidija,182,2517154,Cannot tell based on the abstract,, Nodules diameters , Placebo , Infliximab ,0,
lidija,182,2517154,No significant difference,No effect of treatment was found upon the mean diameters of the nodules as measured by TVU., Nodules diameters , Placebo , Infliximab ,0,
lidija,202,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
lidija,202,4106715,Significantly increased,"3â??AmNic-rEPA recipients in the high Ab group were significantly more likely to attain 8 weeks of continuous abstinence from weeks 19 through 26 than placebo (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14â??6.37).", Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
lidija,168,2864284,Cannot tell based on the abstract,, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,168,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,190,2517154,Cannot tell based on the abstract,, Pain killers intake , Placebo , Infliximab ,0,
lidija,190,2517154,No significant difference,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01), and higher dysmenorrhea scores (P < 0.001 for physician assessment, for patient VAS scales and for patient diary).", Pain killers intake , Placebo , Infliximab ,0,
lidija,194,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65â??0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59â??0.89)", Labour dystocia , Normal unit & Special unit , Midwife-led unit ,0,
lidija,186,2517154,Cannot tell based on the abstract,, Surgery duration , Placebo , Infliximab ,0,
lidija,186,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Surgery duration , Placebo , Infliximab ,0,
lidija,136,2871176,Cannot tell based on the abstract,, HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,136,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),", HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,116,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,116,2871176,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001),", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,173,2864284,Cannot tell based on the abstract,, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,173,2864284,Significantly increased,"<td align=""left"">Median white blood cells Ã?10<sup>9</sup>/ml, median (range)</td><td align=""left"">6.0 (3.6-54)</td><td align=""left"">6.6 (3.0-12.4)</td><td align=""left"">0.02</td>", Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,167,3001156,Cannot tell based on the abstract,, Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,167,3001156,Significantly decreased,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">Chi-square trend test for care from unqualified providers, comparison group</td><td align=""left"" colspan=""6"" rowspan=""1"" valign=""top"">Chi-square for linear trend=0.90, df=1, p=0.34</td>", Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,139,2871176,Cannot tell based on the abstract,, HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,139,2871176,No significant difference,There were no significant differences between treatments for HOMA-IR., HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,213,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups", IL-6r (ng/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,110,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,110,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,144,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,144,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â??2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â??2.3 mmHg).", Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,165,3001156,Cannot tell based on the abstract,, Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,165,3001156,Significantly increased,". Increases were observed in self-referral of sick newborns for care, compliance after referral by the CHWs, and care-seeking from qualified providers and from the Kumudini Hospital,", Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,109,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
lidija,109,2871176,Significantly decreased,Rosiglitazone also was superior to placebo (P < 0.0001)., HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
lidija,106,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,106,2871176,Significantly decreased,"All liraglutide doses were superior to placebo (P < 0.0001),", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,149,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,149,2871176,Significantly increased,"Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002)", Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,104,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001,", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,180,2864284,Cannot tell based on the abstract,, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,180,2864284,No significant difference,"<td align=""left"">Haemoglobin concentration, mean g/dl (SD)</td><td align=""left"">10.9 (1.46)</td><td align=""left"">10.9 (1.42)</td><td align=""left"">0.99</td>,<td></td><td></td><td></td><td></td>", Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,111,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,111,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ? 6.5%, respectively, compared with 8% and 4% for placebo", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,187,2517154,Cannot tell based on the abstract,, Bleeding during surgery , Placebo , Infliximab ,0,
lidija,187,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Bleeding during surgery , Placebo , Infliximab ,0,
lidija,157,2708184,Cannot tell based on the abstract,, Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
lidija,157,2708184,No significant difference,"<td colspan=""8""><hr></td>", Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
lidija,122,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,122,2871176,Significantly decreased,"The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).", ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,126,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,126,2871176,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05)", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,158,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,158,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,125,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [?2.5 to ?2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (?0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (?1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,183,2517154,Cannot tell based on the abstract,, Endometrial thickness , Placebo , Infliximab ,0,
lidija,183,2517154,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3â??18) and 7.8 (1.9â??11) mm and for the placebo group 7.7 (1.8â??23) and 8.2 (3â??15) mm, respectively.", Endometrial thickness , Placebo , Infliximab ,0,
lidija,175,2864284,Cannot tell based on the abstract,, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,175,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,133,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,133,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02), Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,171,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Superiority of treatment given by survival curves , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,146,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,146,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7â??1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,127,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,127,2871176,Significantly decreased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05)", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,174,2864284,Cannot tell based on the abstract,, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,174,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,118,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,118,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ? 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%), ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,185,2517154,Cannot tell based on the abstract,, Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
lidija,185,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis),", Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
lidija,142,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,142,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â??2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9â??2.3 mmHg)", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,162,2708184,Cannot tell based on the abstract,, Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,162,2708184,Significantly increased,"<td colspan=""8""><hr></td>", Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,129,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,129,2871176,No significant difference,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,131,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,131,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ? 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,140,2871176,Cannot tell based on the abstract,, HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,140,2871176,No significant difference,There were no significant differences between treatments for HOMA-IR., HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,203,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
lidija,203,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53â??12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
lidija,170,2864284,Cannot tell based on the abstract,, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,170,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,150,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,150,2871176,Significantly increased,Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,124,2871176,Cannot tell based on the abstract,, Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,124,2871176,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5â??2.4 mmol/l; P < 0.0001), Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,113,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,113,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ? 0.0003),", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,145,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,145,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7â??1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,161,2708184,Cannot tell based on the abstract,, Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,161,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,102,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,102,2871176,Significantly decreased,An 0.7-mmol/l greater reduction in FPG was achieved with either liraglutide 1.2 or 1.8 mg compared with rosiglitazone (P ? 0.006) after 26 weeks., Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,101,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,101,2871176,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,108,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,108,2871176,No significant difference,Liraglutide 0.6 mg was non-inferior to rosiglitazone, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,181,2517154,Cannot tell based on the abstract,, Severity of pain , Placebo , Infliximab ,0,
lidija,181,2517154,Invalid Prompt,, Severity of pain , Placebo , Infliximab ,1, there is no data for pain levels
lidija,141,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,141,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6â??2.8 mmHg), they were not significantly different from placebo", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,153,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,153,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,210,2206488,Cannot tell based on the abstract,, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,210,2206488,Significantly decreased,Systemic vascular resistance index (dyn s/cm5 m2)	0.005, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,196,3187863,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11â??1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16â??2.13).", Pain relief: Epidural anesthesia , Normal unit & Special unit , Midwife-led unit ,0,
lidija,115,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,115,2871176,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,193,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit & Special unit , Special unit ,0,
lidija,200,2688140,Cannot tell based on the abstract,, The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
lidija,200,2688140,No significant difference,"The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups.", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
lidija,138,2871176,Cannot tell based on the abstract,, HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,138,2871176,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)", HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,148,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,148,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ? 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01)., Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,152,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,152,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048),", Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,151,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,151,2871176,Significantly increased,Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,105,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,105,2871176,Significantly decreased,"All liraglutide doses were superior to placebo (P < 0.0001),", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,333,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002), Baseline-adjusted average 12-hour FEV1 on the day of randomization , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,335,3580134,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ? 0.029), only budesonide/formoterol 320/9 ?g demonstrated this effect at the end of treatment (p ? 0.004)", Mean FEV1 at 12 hours at end of treatment , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,390,2690844,Significantly increased,"Both the surgeons and the patients found the scar resulting from the transverse incision to be more cosmetically pleasing (PÂ <Â 0.0001 and PÂ =Â 0.03, respectively,", Better cosmetic appearance of the incision as subjectively assessed by surgeons , Midline incision , Transverse incision ,0,
lidija,359,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Awakening-free nights percentage improvement , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,425,1187893,Significantly increased,"<td colspan=""7""><hr></td>", SF-36 Mental Component Summary scale at 6 weeks , No exercise , Exercise ,0,
lidija,348,3580134,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 ?g and 160/9 ?g versus placebo (37% and 41%, respectively; p < 0.001)", Amount of exacerbations per patient-treatment year , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,330,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002), Mean FEV1 at 12 hours on the day of randomization , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,331,3580134,No significant difference,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ? 0.029), only budesonide/formoterol 320/9 ?g demonstrated this effect at the end of treatment (p ? 0.004) [table II].", Mean FEV1 at 12 hours on the day of randomization , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,234,3090298,No significant difference,Significant differences were not found between treatment groups in contrast sensitivity (P ? 0.156) or CDVA (P = 0.800) at postoperative 6 months., 1 line or more of CDVA at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
lidija,325,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002), Mean FEV1 at 12 hours at end of treatment , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,383,2721929,Significantly decreased,The decrease in frequency was significantly greater in the Co group than in the BT group (p<0.05)., Micturition frequency , Bladder training only (BT) , Bladder training plus tolterodine (Co) ,0,
lidija,410,2575601,No significant difference,"<td></td><td></td><td colspan=""6""><hr></td>", Infection , Pentobarbital , Thiopental ,0,
lidija,244,2922723,No significant difference,No statistically significant change in FEV1% or oxygen saturation was observed after either HFCWO or usual ACTs compared with baseline., FEV1% , Usual airway clearance techniques , High frequency chest wall oscillation ,0,
lidija,468,3387601,Cannot tell based on the abstract,, side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
lidija,468,3387601,No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients., side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
lidija,214,1475568,No significant difference,"61% of patients in the control group had at least one hospitalization or died, and 42% of patients in the intervention group had at least 1 hospitalization or died (p = 0.13).", Hospitalization or death , Standard information about self-care , Follow-up and thorough education on self-care ,0,
lidija,364,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003]", Sputum score improvement , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,215,1475568,Significantly increased,"Significantly more patients in the intervention group than in the control group reported daily weight measurement at 12 months (79% vs. 29%, p < 0.001).", Daily weight monitoring at the end of treatment , Standard information about self-care , Follow-up and thorough education on self-care ,0,
lidija,382,3580134,No significant difference,"The total incidence of pneumonia-related AEs (pneumonia, bronchopneumonia, lobar pneumonia and pneumonia staphylococcal) was similar for budesonide/formoterol 320/9 ?g and 160/9 ?g (4.0% and 3.4%, respectively) compared with formoterol (3.4%) and placebo (5.0%)", Incidence of pneumonia , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,317,3580134,Significantly increased,"Although improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001), budesonide/formoterol 320/9 ?g also resulted in significantly greater improvements compared with formoterol (p = 0.023)", 1-hour post-dose FEV1 improvements , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,445,1468428,No significant difference,Enemas didn't significantly change episiorraphy dehiscence rates (21/182 [12%] with enema v 32/190 [17%] without enema; P = 0.30)., Episiorraphy dehiscence rates , no enema , 1 litre saline enema ,0,
lidija,248,2922723,No significant difference,No significant differences were observed in VAS scores for comfort or urinary leakage between HFCWO and usual ACT, Visual analogue scale scores for comfort , Usual airway clearance techniques , High frequency chest wall oscillation ,0,
lidija,263,2691927,Significantly increased,Operating time in the laparoscopy group was significantly longer than in the open group (75Â min versus 50Â min)., Surgery duration , Conventional open approach , Laparoscopic surgery ,0,
lidija,304,2817867,No significant difference,"Rates of ICU admission (6.5% of patients overall), and length of stay (median of 7 days for all patients; range 1 to 48) were not significantly different between patients having hepatic resection and RFA.", Need for ICU  , Hepatic resection , Radiofrequency ablation ,0,
lidija,322,3580134,Significantly increased,Mean FEV1 at 12 hours and baseline-adjusted average 12-hour FEV1 were significantly improved with both budesonide/formoterol dosages compared with placebo on the day of randomization and at end of treatment (p ? 0.002), Mean FEV1 at 12 hours on the day of randomization , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,478,2447617,No significant difference,there was no statistical significance between the two groups (P > 0.05). Instances of complications and adverse events associated with the administration of progesterone were not found., Instances of complications and adverse events , placebo , progesterone ,0,
lidija,411,2575601,No significant difference,"<td></td><td></td><td colspan=""6""><hr></td>", Hypotension , Pentobarbital , Thiopental ,0,
lidija,476,2447617,Significantly decreased,The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05)., The mortality rate , placebo , progesterone ,0,
lidija,437,1201146,Cannot tell based on the abstract,, 50% reduction in pain , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
lidija,437,1201146,Significantly increased,"<td colspan=""3""><hr></td>", 50% reduction in pain , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
lidija,483,2899760,Significantly increased,Trabecular Metal showed a lower fusion rate than the Smithâ??Robinson technique with autograft after single-level anterior cervical fusion without plating., Radiological fusion , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ?¢ (TM) , raditional Smithâ??Robinson (SR) procedure with autograft  ,0,
lidija,484,3108665,Significantly decreased,"Administration of somatostatin reduced the exocrine granule number, and the patients suffered from fewer postoperative complications.", Postoperative complications , No medication was given to the control group , somatostatin ,0,
lidija,421,1187893,Significantly decreased,"<td colspan=""7""><hr></td>", Knee injury and Osteoarthritis Outcome Score , No exercise , Exercise ,0,
lidija,399,2690844,No significant difference,No significant difference was noted in the skin-to-skin time (in min) for the two different incisions (TableÂ 2)., Skin-to-skin time , Midline incision , Transverse incision ,0,
lidija,239,3090298,No significant difference,Significant differences were not found between treatment groups in contrast sensitivity (P ? 0.156), Contrast sensitivity at 1 month seen at 12 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
lidija,379,3580134,No significant difference,"The total incidence of pneumonia-related AEs (pneumonia, bronchopneumonia, lobar pneumonia and pneumonia staphylococcal) was similar for budesonide/formoterol 320/9 ?g and 160/9 ?g (4.0% and 3.4%, respectively) compared with formoterol (3.4%) and placebo (5.0%)", Incidence of pneumonia , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,247,2922723,Significantly decreased,"Significantly more sputum was expectorated during a single treatment session and over a 24?h period (mean difference 4.4?g and 6.9?g, respectively) with usual ACTs than with HFCWO (p<0.001).", Sputum expectoration between treatments in a 24-hour period , Usual airway clearance techniques , High frequency chest wall oscillation ,0,
lidija,252,1831737,No significant difference,"Despite greater programme activity and knowledge in the intervention communities, the incidence rate ratio of HIV-1 was 1.27 (95% confidence interval [CI] 0.92â??1.75) compared to the control communities.", HIV-1 incidence , Communities that received standard Government services , Communities that received additional education and preventive measures ,0,
lidija,458,1913177,No significant difference,There was no in-hospital mortality, Postoperative Mortality , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
lidija,336,3580134,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups, Pre-dose inspiratory capacity , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,417,1784771,Significantly increased,"After six hours of ripening, the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007)", Changes in Bishop score after 6 hours , Prostaglandin gel , Prostaglandin gel plus hygroscopic cervical dilators  ,0,
lidija,381,3580134,No significant difference,"The total incidence of pneumonia-related AEs (pneumonia, bronchopneumonia, lobar pneumonia and pneumonia staphylococcal) was similar for budesonide/formoterol 320/9 ?g and 160/9 ?g (4.0% and 3.4%, respectively) compared with formoterol (3.4%) and placebo (5.0%)", Incidence of pneumonia , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,454,2720945,Significantly decreased,"Improvement of lung function, dyspnea and quality of life as multiple criteria were statistically significant relative to placebo.", Dyspnea during exercise , placebo , cineole ,0,
lidija,414,2575601,Invalid Prompt,, Intracranial pressure recurrence after treatment withdrawal , Pentobarbital , Thiopental ,1, there is no data on recurrence
lidija,362,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Breathlessness Cough and Sputum Scale improvement , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,419,1784771,No significant difference,"the combined group achieved a greater change in Bishop score (3.6 vs. 2.1, P = 0.007) and tended to have a shorter induction time (21.7 vs. 26.4 hours, P = 0.085).", Induction time , Prostaglandin gel , Prostaglandin gel plus hygroscopic cervical dilators  ,0,
lidija,439,1201146,Cannot tell based on the abstract,, Dry skin at the application site , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
lidija,439,1201146,Significantly increased,"<td colspan=""3""><hr></td>", Dry skin at the application site , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
lidija,350,3580134,Significantly decreased,"significant reductions in the overall number of exacerbations per patient-treatment year were observed with budesonide/formoterol 320/9 ?g and 160/9 ?g versus placebo (37% and 41%, respectively; p < 0.001) and formoterol (25% and 29%, respectively; p ? 0.004)", Amount of exacerbations per patient-treatment year , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,274,2691927,Significantly increased,"The VAS score for appearance of the scar left by the respective procedures (subjectively recorded in the same way as pain) differed by 2.3 points, favoring the laparoscopic procedure (7.7 vs. 5.4; PÂ =Â 0.033)", Better scar appearance score as measured by visual analog scale , Conventional open approach , Laparoscopic surgery ,0,
lidija,339,3580134,No significant difference,No significant differences in pre-dose IC were observed among the treatment groups, Pre-dose inspiratory capacity , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,405,2690844,Significantly decreased,Transverse incisions were found to be significantly shorter than midline incisions, Scar length , Midline incision , Transverse incision ,0,
lidija,343,3580134,Significantly increased,Improvements from baseline were apparent at the first assessment (pre-dose FEV1 at end of month 1; 1-hour post-dose FEV1 at day of randomization) and overall maintained over the 12-month treatment period for both budesonide/formoterol dosages, 1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period  , Placebo , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,446,1468428,Invalid Prompt,, You must have prompts generated from different sections. ,2,1,1,"There is no prompt

With respect to You must have prompts generated from different sections., characterize the reported difference between patients receiving 1 and those receiving 2."
lidija,449,2720945,Cannot tell based on the abstract,, change of FVC and VC , placebo , cineole ,0,
lidija,449,2720945,No significant difference,The difference concerning change of FVC and VC between both treatment groups was not clinically relevant., change of FVC and VC , placebo , cineole ,0,
lidija,245,2922723,No significant difference,No statistically significant change in FEV1% or oxygen saturation was observed after either HFCWO or usual ACTs compared with baseline, O2 saturation , Usual airway clearance techniques , High frequency chest wall oscillation ,0,
lidija,301,2817867,Significantly decreased,The operative time was significantly longer for the resection group compared to the RFA group (median of 269 minutes (range 118 to 452) versus 204 minutes (range 113 to 316); P < .0005), Duration of surgery , Hepatic resection , Radiofrequency ablation ,0,
lidija,424,1187893,No significant difference,"<td colspan=""7""><hr></td>", Baseline characteristics , No exercise , Exercise ,0,
lidija,225,1475568,No significant difference,39% of patients in the control group and 34% of patients in the intervention group had at least one hospitalization for cardiac causes (p = 0.55)., Cardiac-related hospitalization , Standard information about self-care , Follow-up and thorough education on self-care ,0,
lidija,464,3387601,Significantly decreased,Children receiving PE had a significantly shorter period of mechanical ventilation compared to those receiving IVIG., Period of mechanical ventilation  , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
lidija,354,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Dyspnoea score improvement , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,426,1187893,No significant difference,"<td colspan=""7""><hr></td>", SF-36 Mental Component Summary scale at 6 months , No exercise , Exercise ,0,
lidija,398,2690844,No significant difference,"The total duration of the procedures until extubation (in min) did not differ between the midline and transverse incisions (71.0Â Â±Â 30.5 and 67.0Â Â±Â 27.3, respectively, PÂ =Â 0.34).", Surgery duration , Midline incision , Transverse incision ,0,
lidija,240,3090298,Significantly decreased,"At 6 months contrast sensitivity in the PRK group was still significantly decreased from baseline at 3 cpd (P = 0.013),", Contrast sensitivity at 6 months seen at 3 cpd , Pre-surgery baseline , Photo-refractive keratectomy (PRK) ,0,
lidija,288,1871574,No significant difference,"<td></td><td colspan=""5""><hr></td>", Socio-economic position , Usual care , Smoking cessation advice and NRT offered ,0,
lidija,284,2361806,Significantly increased,"Compared with ELF, the ILF regimen extended median progression-free survival,", Progression-free survival , Etoposide with 5-fluorouracil plus leucovorin (ELF) , Irinotecan with high-dose 5-fluorouracil plus leucovorin (ILF) ,0,
lidija,271,2691927,No significant difference,Location of the perforated ulcers was distributed equally between groups., Ulcer location  , Conventional open approach , Laparoscopic surgery ,0,
lidija,303,2817867,Significantly decreased,transfusion requirements (44% of patients versus 5%; P < .0005) were higher for resection than for RFA., Transfusion requirements , Hepatic resection , Radiofrequency ablation ,0,
lidija,229,3090298,No significant difference,Visual acuities were not statistically different between the groups at 3 or 6 months., Uncorrected distance visual acuity at 6 months , Thin-flap laser in situ keratomileusis (LASIK) , Photo-refractive keratectomy (PRK) ,0,
lidija,251,2922723,No significant difference,Neither HFCWO nor any of the usual ACTs were associated with any adverse clinical events., Adverse events , Usual airway clearance techniques , High frequency chest wall oscillation ,0,
lidija,375,3580134,Significantly decreased,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047)", Overall use of daily rescue medication  improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,342,3580134,Significantly increased,"improvements in 1-hour post-dose FEV1 were significantly greater for both budesonide/formoterol dosages compared with placebo (primary comparison; p < 0.001),", 1-hour post-dose inspiratory capacity mean improvements from baseline to the average over the randomized treatment period  , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,260,1831737,Significantly increased,"More respondents in the intervention communities than in the control communities attended an HIV/AIDS meeting (41% versus 28%, prevalence rate ratio 1.44 [95% CI 1.33â??1.56], p < 0.001)", HIV/AIDS meeting attendance , Baseline communities that received standard Government services , Baseline communities that received additional education and preventive measures ,0,
lidija,334,3580134,Significantly increased,"Although both budesonide/formoterol dosages demonstrated significant improvements in mean FEV1 at 12 hours and in baseline-adjusted average 12-hour FEV1 compared with formoterol on the day of randomization (p ? 0.029), only budesonide/formoterol 320/9 ?g demonstrated this effect at the end of treatment (p ? 0.004) [table II]. Fig. 4", Baseline-adjusted average 12-hour FEV1 at end of treatment , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,438,1201146,Cannot tell based on the abstract,, good or very good PGA response and OMERACT-OARSI responder , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
lidija,438,1201146,Significantly increased,"<td colspan=""3""><hr></td>", good or very good PGA response and OMERACT-OARSI responder , vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
lidija,358,3580134,Significantly increased,"Significantly greater improvements in COPD symptom variables were observed for both budesonide/formoterol dosages versus placebo for all variables (BCSS, dyspnoea score, cough score, sputum score, sleep score, percentage of awakening-free nights and total daily rescue medication use) [p ? 0.003].", Sleep score improvement , Placebo , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,371,3580134,No significant difference,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights,", Sleep score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,409,2575601,Significantly increased,"<td></td><td></td><td colspan=""6""><hr></td>", Intracranial pressure control , Pentobarbital , Thiopental ,0,
lidija,413,2575601,Invalid Prompt,, Mean barbiturate coma length , Pentobarbital , Thiopental ,1, there is no data on coma length
lidija,460,1913177,Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR., Reherniation , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
lidija,373,3580134,No significant difference,"Compared with formoterol, mean improvements were significantly greater with budesonide/formoterol 320/9 ?g (p ? 0.038) for all COPD symptom variables except sputum score and percentage of awakening-free nights, and with budesonide/formoterol 160/9 ?g (p ? 0.047) for all COPD symptom variables except BCSS, dyspnoea and sputum score", Cough score improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,471,2430614,Significantly increased,"In the per-protocol (PP) analyses there were no statistically significant differences in the rates of early treatment, late treatment, parasitological or clinical failures at day 14 between the three groups,However, the parasitological and clinical failure rate at day 28 (PCF28) uncorrected for re-infections was significantly lower in the AS+AQ group (14.6%) compared to the AL (27.6%) or AS+CD (28.1%) groups", parasitological or clinical failure rates by day 14 or day 28 in G6PD deficient children , artemether-lumefantrine (AL) , Artesunate+amodiaquine (AS+AQ) ,0,
lidija,416,2575601,No significant difference,"<td align=""left"">SOFA maximum<sup>f</sup></td><td align=""left"">11 (10 to 12)</td><td align=""left"">11 (10 to 12)</td><td align=""left"">0.94</td>", Sepsis related Organ-Failure Assessment (SOFA) maximum score during treatment , Pentobarbital , Thiopental ,0,
lidija,435,1201146,Significantly decreased,"<td colspan=""3""><hr></td>"," Pain, physical function, PGA, stiffness  ", vehicle control solution (carrier with no diclofenac) , topical diclofenac solution (PennsaidÂ®) ,0,
lidija,313,3580134,Significantly increased,Improvements in pre-dose FEV1 were significantly greater for budesonide/formoterol 320/9 ?g compared with formoterol (primary comparison; p = 0.008), Pre-dose FEV1 improvement , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 320/9 ?g ,0,
lidija,353,3580134,Significantly increased,Improvements in SGRQ total score were significantly greater for both budesonide/formoterol dosages compared with placebo (p ? 0.006) and for budesonide/formoterol 160/9 ?g compared with formoterol (p = 0.006; t, Improvements in St. George's Respiratory Questionnaire overall score , Formoterol DPI 9 ?g , Budesonide/formoterol pMDI 160/9 ?g ,0,
lidija,466,3387601,No significant difference,A total of 20/21 (95.2%) and 18/20 (90%) children in the PE and IVIG groups respectively could walk unaided within four weeks after PICU discharge (p = 0.606)., could walk unaided within four weeks after PICU discharge , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
lidija,392,2690844,Significantly decreased,"More patients having undergone a midline incision, reported pain on day one, two and three postoperatively than patients from the transverse group.", Pain on day two after surgery , Midline incision , Transverse incision ,0,
lidija,412,2575601,No significant difference,"<td></td><td></td><td colspan=""6""><hr></td>", Administration of hyperosmolar treatments , Pentobarbital , Thiopental ,0,
lidija,513,2829413,Significantly decreased,"non-high-density lipoprotein cholesterol (- 42.93 Ã?Â± 13.15 vs. - 35.52 Ã?Â± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 Ã?Â± 18.85 vs. - 32.57 Ã?Â± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.", Levels of non-high-density lipoprotein cholesterol after 6 weeks of treatment , Atorvastatin , Rosuvastatin ,0,
lidija,559,2888205,Significantly decreased,"<th></th><th colspan=""6""><hr></th>", perceived functional deficits , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
lidija,555,2830179,Significantly increased,"<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>", Timed loaded standing test (s) , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
lidija,511,2829413,Significantly decreased,"After 6 weeks of treatment, greater reductions in total cholesterol (- 35.94 Ã?Â± 11.38 vs. - 30.07 Ã?Â± 10.46%, p < 0.001), LDL-C (48.04 Ã?Â± 14.45 vs. 39.52 Ã?Â± 14.42%, p < 0.001), non-high-density lipoprotein cholesterol (- 42.93 Ã?Â± 13.15 vs. - 35.52 Ã?Â± 11.76%, p < 0.001), and apolipoprotein-B (- 38.7 Ã?Â± 18.85 vs. - 32.57 Ã?Â± 17.56%, p = 0.002) levels were observed in the rosuvastatin group as compared to the atorvastatin group.", Total cholesterol after 6 weeks of treatment , Atorvastatin , Rosuvastatin ,0,
lidija,494,2253708,Significantly increased,"<th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th><th align=""left"" colspan=""3"" rowspan=""1""><hr></th>", 24-hour point prevalence abstinence , Practitioner-delivered brief advice , Tailored letters ,0,
lidija,547,2666722,Cannot tell based on the abstract,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,0,
lidija,547,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1, there is no data on the IgG
lidija,520,1261533,No significant difference,"n both groups, the PCR adjusted cure rates by day 42 were high: 98.8% (95% CI 96.4, 99.6%) for artemether-lumefantrine and 96.3% (95% CI 93.1, 98.0%) for artesunate-mefloquine.", New P. falciparum infections during the 42-day follow-up , Mefloquine-artesunate , Artemether-lumefantrine ,0,
lidija,567,3490871,Significantly increased,A higher percentage of control participants continued smoking (74% vs. 66%)., Smoking cessation , Usual care comprised of 7Ã¢â?¬â?°weeks of group support sessions , 24-week intervention focussed on improving food choice and minimising weight gain ,0,
lidija,614,4794897,Significantly decreased,PYD and CTX-I decreased significantly in arm A., beta-isomer of carboxy-terminal telopeptide of type I collagen , passive physical therapy , resistance training dyrung radiation therapy ,0,
lidija,499,2956883,No significant difference,"In the primary efficacy analysis, incidence of HIV-1 did not differ between groups at discontinuation of 2% PRO2000 or study end (table 2). Equally, incidence of HIV-1 did not differ between groups in the second analysis that did not censor for pregnancy (table 2).", HIV-1 incidence , Placebo gel , 0Ã?Â·5% PRO2000 gel ,0,
lidija,575,4577567,Significantly increased,Kinematic parameters measured before and after the 3-week training in RWM showed increased stride length (4.54%; p<0.0001), stride length , free stride frequency , stride frequency manipulation ,0,
lidija,505,2376383,Significantly increased,The mean weight loss after 5 weeks of radiation was less in the PTA group by 1.3Ã¢â?¬â?°kg (s.d. 3.0) than in the placebo group 2.8Ã¢â?¬â?°kg (s.d. 2.9) (P=0.05)., Weight loss , Placebo lozenge , PTA lozenge ,0,
lidija,564,2888205,No significant difference,"<th></th><th colspan=""6""><hr></th>", Body mass index (BMI) , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
lidija,605,5062194,Significantly increased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group., postoperative satisfaction ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
lidija,538,2722000,Significantly decreased,"On multivariate analysis, antibiotic prophylaxis (relative hazard: 0.248, 95% confidence interval (CI): 0.067-0.919, p=0.037) and bacterial infection (relative hazard: 3.901, 95% CI: 1.053-14.448, p=0.042) were two independent determinants of early rebleeding.", Enteric bacteria , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
lidija,524,3349250,No significant difference,"overall survival was also longer with sunitinib than with IFN-Ã?Â±, although the difference did not reach statistical significance", Overall survival , Interferon (IFN)-Ã?Â± , Sunitinib ,0,
lidija,550,125315,Cannot tell based on the abstract,, The 28-day mortality , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
lidija,550,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", The 28-day mortality , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
lidija,530,2361948,No significant difference,No significant differences between study arms were observed in the degree of relief of all analysed symptoms., degree of relief of all analysed symptoms , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16Ã¢â?¬â?°Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20Ã¢â?¬â?°Gy/5 fractions (fr)/5 days (arm A) ,0,
lidija,493,2363351,No significant difference,"Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-Ã?Â³.", Toxicity , Cisplatin and Cyclophosphamide ," Cisplatin and Cyclophosphamide, plus subcutaneous IFN-Ã?Â³  ",0,
lidija,607,5062194,Cannot tell based on the abstract,, No statistical analysis because they are in tables ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
lidija,607,5062194,Invalid Prompt,, No statistical analysis because they are in tables ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,1," With respect to No statistical analysis because they are in tables, characterize the reported difference between patients receiving intravenous dose of 0.035 mg/kg of midazolam and those receiving equal volume of normal saline, 30 min before spinal anesthesia."
lidija,528,2361948,Significantly decreased,Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3 months; P=0.016)., Overall survival time , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16Ã¢â?¬â?°Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20Ã¢â?¬â?°Gy/5 fractions (fr)/5 days (arm A) ,0,
lidija,590,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Driving a car</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Ã?Â·1</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">7Ã?Â·0</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Ã?Â·78 (1Ã?Â·45, 2Ã?Â·19)</td>", Driving a car , surgery , UltrasoundÃ¢â?¬?guided foam sclerotherapy ,0,
lidija,532,3221331,No significant difference,Continuous abstinence at 6 months was 26.4% (29/110) in the intervention group and 27.6% (32/116) in the control group (P = .8), Continuous abstinence at 6 months , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
lidija,497,2364533,No significant difference,"erythromycin had little impact on reducing low birth weight (8% vs. 11%, P = 0.4)", Low birth weight  , Placebo , Erythromycin ,0,
lidija,525,3349250,Significantly increased,"However, the mean time spent without symptoms of disease progression or toxicity of treatment (i.e., TWiST) was 151 days higher in the sunitinib than in the IFN-Ã?Â± arm (95% CI:", Quality-of-life scores , Interferon (IFN)-Ã?Â± , Sunitinib ,0,
lidija,554,2830179,Significantly increased,"<th></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""2""><hr></th><th colspan=""1""><hr></th>", Qualeffo Total (0-100) , received no treatment , attended individual sessions with an experienced clinician once a week for 10 weeks and performed daily home exercises with adherence monitored by a self-report diary ,0,
lidija,516,2829413,No significant difference,". Changes in glucose and insulin levels, and homeostasis model assessment of insulin resistance index were not significantly different between the two groups.", Changes in glucose and insulin levels , Atorvastatin , Rosuvastatin ,0,
lidija,579,5294349,No significant difference,"This combination gives a pair of landmarks with somewhat higher error after rigid body registration, but the combined effect on the evaluation of relative movement is theoretically negligible, since these errors tend to eliminate each other.", datasets of 3D coordinates , 2Ã¢â?¬â??4 stereo radiograph pair examinations , CT scan ,0,
lidija,598,4819709,No significant difference,"<td align=""center"" colspan=""1"" id=""bjs10081-ent-0415"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0416"" rowspan=""1"" valign=""top"">20Ã?Â·0</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0417"" rowspan=""1"" valign=""top"">15Ã?Â·8</td>,<td align=""left"" colspan=""1"" id=""bjs10081-ent-0450"" rowspan=""1"" valign=""top"">Participation items</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0451"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0452"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0453"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0454"" rowspan=""1"" valign=""top""></td>,<td align=""center"" colspan=""1"" id=""bjs10081-ent-0484"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0485"" rowspan=""1"" valign=""top"">21Ã?Â·1</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0486"" rowspan=""1"" valign=""top"">15Ã?Â·4</td>,<td align=""center"" colspan=""1"" id=""bjs10081-ent-0508"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0509"" rowspan=""1"" valign=""top"">55Ã?Â·5</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0510"" rowspan=""1"" valign=""top"">62Ã?Â·6</td>"," Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (>Ã¢â?¬â?°15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work/employment, Going out socially, Sporting activity or exercise ", UltrasoundÃ¢â?¬?guided foam sclerotherapy , Endovenous laser ablation ,0,
lidija,518,1261533,No significant difference,There was no difference in fever clearance times between the two treatment groups, Fever clearance times , Mefloquine-artesunate , Artemether-lumefantrine ,0,
lidija,521,1261533,No significant difference,"In both groups, the PCR adjusted cure rates by day 42 were high: 98.8% (95% CI 96.4, 99.6%) for artemether-lumefantrine and 96.3% (95% CI 93.1, 98.0%) for artesunate-mefloquine.", PCR-adjusted cure rates after 42 days , Mefloquine-artesunate , Artemether-lumefantrine ,0,
lidija,542,2650992,No significant difference,"Overall, the fibrin glue and control groups were similar in terms of drainage duration, overall drain output, and incidence of seroma.", overall drain output , control group , fibrin glue group (glue sprayed onto the axillary dissection site) ,0,
lidija,509,1964758,Significantly increased,"<td colspan=""4""><hr></td>", 4-year survivorship , BioModularÃ?Â® shoulder prosthesis , Redesigned Nottingham TSR prosthesis ,0,
lidija,585,4819709,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">9Ã?Â·3</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">17Ã?Â·5</td>", Moving from standing to sitting without discomfort , surgery , UltrasoundÃ¢â?¬?guided foam sclerotherapy ,0,
lidija,507,2376383,No significant difference,"During the radiation period the colonisation in the PTA group was less than in the placebo group, but the difference was only significant in the second week of radiation (P=0.05)", Aerobic Gram-negative bacilli colonisation at 3-5 weeks , Placebo lozenge , PTA lozenge ,0,
lidija,527,3349250,Significantly increased,sunitinib showed significant improvement in progression-free survival (PFS) compared with interferon (IFN)-Ã?Â±., Duration of median PFS , Interferon (IFN)-Ã?Â± , Sunitinib ,0,
lidija,565,2888205,Cannot tell based on the abstract,, Center for Epidemiologic Studies Depression Scale (CES-D) , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
lidija,565,2888205,No significant difference,"<td align=""left"">â??Post intervention</td><td align=""center"">73</td><td align=""center"">21.6 Â± 9.8</td><td align=""center"">21.2 Â± 11.3</td><td align=""center"">.4 (-5.3 to 4.6)</td><td align=""center"">0.888</td><td align=""center"">.04</td>", Center for Epidemiologic Studies Depression Scale (CES-D) , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
lidija,570,5256321,Cannot tell based on the abstract,," he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I)  "," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
lidija,570,5256321,Significantly increased,"experimental group showed significant improvements in all testsÃ¢â?¬â??BBS (p=0.001), TUG (p=0.001), forward FRT (p=0.001), affected lateral FRT"," he Berg Balance Scale (BBS), Timed Up and Go Test (TUG), Functional Reach Test (FRT), the Korean version of the Fall Efficacy Scale-International (KFES-I)  "," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
lidija,492,2363351,No significant difference,Complete clinical responses were observed in 68% with IFN-Ã?Â³ versus 56% in controls (n.s.), Full clinical responses , Cisplatin and Cyclophosphamide ," Cisplatin and Cyclophosphamide, plus subcutaneous IFN-Ã?Â³  ",0,
lidija,549,125315,No significant difference,"<td></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td><td colspan=""3""><hr></td>", Sequential Organ Failure Assessment (SOFA) score  , received only standard therapy for sepsis , received standard therapy for sepsis and physiological-dose steroid therapy for 10 days; ,0,
lidija,562,2888205,No significant difference,"<th></th><th colspan=""6""><hr></th>", Fatigue severity scale , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
lidija,537,2722000,Cannot tell based on the abstract,, The incidence of bacterial infection , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
lidija,537,2722000,Significantly decreased,"Antibiotic prophylaxis decreased infection (3.2% vs. 15.5%, p=0.026).", The incidence of bacterial infection , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
lidija,523,3349250,Significantly increased,There were more reported occurrences of most general adverse events of all grades in the sunitinib arm than in the IFN-Ã?Â± arm, Adverse events , Interferon (IFN)-Ã?Â± , Sunitinib ,0,
lidija,592,4819709,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">6Ã?Â·2</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">17Ã?Â·9</td>", Looking after children , surgery , UltrasoundÃ¢â?¬?guided foam sclerotherapy ,0,
lidija,246,2922723,Significantly decreased,"Significantly more sputum was expectorated during a single treatment session and over a 24â??h period (mean difference 4.4â??g and 6.9â??g, respectively) with usual ACTs than with HFCWO (p<0.001).", Sputum expectoration over a 24-hour period , Usual airway clearance techniques , High frequency chest wall oscillation ,0,
lidija,434,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes."," Neonatal outcomes were evaluated by Apgar score &lt;7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth ", Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,430,3187863,Cannot tell based on the abstract,, Oxytocin infusion for augmentation of labour , Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,430,3187863,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59â??0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56â??0.86)", Oxytocin infusion for augmentation of labour , Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,429,3187863,Cannot tell based on the abstract,, Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,429,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65â??0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59â??0.89)", Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,651,1468428,No significant difference,"We found no significant differences in puerperal or neonatal infection rates (Puerperal infection: 41/190 [22%] with enema v 26/182 [14%] without enema; RR 0.66 CI 95%: 0.43 to 1.03; neonatal infection 38/191 [20%] with enema v 40/179 [22%] without enema; RR 1.12, 95% CI 95% 0.76 to 1.66), and median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24)", Puerperal and neonatal infection rates  , no enema , 1 litre saline enema ,0,
lidija,840,4819709,Cannot tell based on the abstract,," walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment ", Ultrasound?guided foam sclerotherapy , Endovenous laser ablation ,0,
lidija,840,4819709,Significantly decreased,"<td align=""center"" colspan=""1"" id=""bjs10081-ent-0431"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0432"" rowspan=""1"" valign=""top"">19Â·8</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0433"" rowspan=""1"" valign=""top"">15Â·2</td>,<td align=""center"" colspan=""1"" id=""bjs10081-ent-0468"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0469"" rowspan=""1"" valign=""top"">8Â·8</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0470"" rowspan=""1"" valign=""top"">6Â·2</td>,<td align=""center"" colspan=""1"" id=""bjs10081-ent-0492"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0493"" rowspan=""1"" valign=""top"">23Â·5</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0494"" rowspan=""1"" valign=""top"">14Â·9</td>"," walking short distances without discomfort, walking long distances, looking after children, full return to normal work/employment ", Ultrasound?guided foam sclerotherapy , Endovenous laser ablation ,0,
lidija,731,2607225,Cannot tell based on the abstract,, cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
lidija,731,2607225,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046)", cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
lidija,860,4139977,No significant difference,Improvement in bowel habit was observed in 33.3% of the probiotic and 36.5% of the placebo group (P = 0.910)., Improvement in bowel habit ," similar placebo, twice daily after a meal for 14 consecutive days "," receive a probiotic compound containing seven bacteria species including Lactobacillus strains, Bifidobacterium strains and Streptococcus thermophiles ",0,
lidija,931,4183415,No significant difference,"there was no difference between arms in adherence measured as completion of all doses (intervention 68.3%, control 69.8%, p [adjusted] = 0.6), or as completion of each dose at the correct time (intervention 33.1%, control 32.6%, p [adjusted] = 0.9)", completion of each dose at the correct time , no text message , receive text message reminders about what advice to provide when dispensing artemether-lumefantrine (AL). ,0,
lidija,681,2847809,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008)., First hemodialysis success , Placebo , Clopidogrel ,0,
lidija,810,5256321,Cannot tell based on the abstract,, trunk strength (BPR score) ," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
lidija,810,5256321,Significantly increased,The improvement levels of the trunk strength (BPR score) for the experimental group using Spine Balance 3D system's evaluation program showed significant improvements at the 15Â° open mode;, trunk strength (BPR score) ," Biodex Balance System (Biodex Medical Systems, Shirley, NY, USA) ", Spine Balance 3D (CyberMedic) ,0,
lidija,920,3015551,No significant difference,"The mean time to remove both tubal segments was not different between techniques (7 minutes, 21 seconds; range, 4 minutes, 25 seconds to 15 minutes, 43 seconds).", The mean time to remove both tubal segments , undergo a tubal resection after bipolar coagulation with Kleppinger forceps , undergo a tubal resection after Pomeroy ligation ,0,
lidija,661,2720945,Cannot tell based on the abstract,," Trouble in breathing, dyspnea in the morning and dyspnea at rest ", placebo , cineole ,0,
lidija,661,2720945,Significantly decreased,"Improvement of lung function, dyspnea and quality of life as multiple criteria were statistically significant relative to placebo."," Trouble in breathing, dyspnea in the morning and dyspnea at rest ", placebo , cineole ,0,
lidija,852,5577662,Cannot tell based on the abstract,, percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
lidija,852,5577662,Significantly increased,"<td colspan=""5"">Week 4</td>", percentage changes in area ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
lidija,921,3015551,No significant difference,"Postoperative pain at 6 hours was scored similarly (median, ligation 4.6, coagulation 4.0 of 10)", Postoperative pain at 6 hours , undergo a tubal resection after bipolar coagulation with Kleppinger forceps , undergo a tubal resection after Pomeroy ligation ,0,
lidija,954,3330821,Significantly decreased,"The BDI-II scores fell from the mean of 17.3 at baseline to 11.0 in the intervention group and to 15.7 in the control group after 4 months (p<0.001, Effect sizeâ??=â??0.69, 95%CI: 0.32 to 1.05).", Beck Depression Inventory-II (BDI-II) after 4 months , Employee Assistance Program , trained psychotherapists in addition to the pre-existing Employee Assistance Program (EAP) ,0,
lidija,648,2600646,Cannot tell based on the abstract,, mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
lidija,648,2600646,No significant difference,"<td colspan=""8""><hr></td>", mean Hb , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
lidija,898,1198254,Significantly decreased,glutathione re-ox ratio values decreased only in case of fermented by ME-3 goat milk., glutathione red-ox ratio , Placebo ," Capsule trial, ME-3 ",0,
lidija,725,2600646,Cannot tell based on the abstract,, Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
lidija,725,2600646,No significant difference,"<td colspan=""8""><hr></td>", Adverse events , dihydroartemisinin-piperaquine (AP) , arthemeter-lumefantrine (AL)  ,0,
lidija,698,3187863,Cannot tell based on the abstract,, Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp;amp; Special unit , Special unit ,0,
lidija,698,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit &amp;amp; Special unit , Special unit ,0,
lidija,895,4140547,Cannot tell based on the abstract,," By month 12, the proportion surviving with a functioning graft ", tacrolimus groups , belatacept groups ,0,
lidija,895,4140547,No significant difference,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""5"" rowspan=""1""><hr></th>"," By month 12, the proportion surviving with a functioning graft ", tacrolimus groups , belatacept groups ,0,
lidija,888,5801479,Significantly decreased,"after the 12-week intervention, compared to the placebo, vitamin D supplementation downregulated gene expression of interleukin (IL)-1Î² (P = 0.02), tumor necrosis factor alpha (TNF-Î±) (P = 0.02) and interferon gamma (IFN-Î³) (P = 0.03) in PBMCs of diabetic HD patients. Additionally, vitamin D supplementation, compared to the placebo, downregulated gene expression of transforming growth factor beta (TGF-Î²) (P = 0.04), protein kinase C (PKC) (P = 0.001), and mitogen-activated protein kinases 1 (MAPK1) (P = 0.02)"," gene expression of transforming growth factor beta (TGF-?), protein kinase C (PKC), mitogen-activated protein kinases 1 (MAPK1)  ", placebo (n = 30) every 2 weeks for 12 weeks ," vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks ",0,
lidija,670,1876597,Significantly decreased,"the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%â??12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%â??16%).", the risk of recurrent parasitemia due to possible recrudescence , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
lidija,926,3220090,Significantly increased,"for parameters such as RW, HKT, and TKT significance was seen only in the experimental group. On comparison between two groups, only TKT showed statistically significance.,It can be concluded that the amount of root coverage obtained with ADMA + CPF was superior compared to CPF alone.", thickness of the keratinized tissue (TKT) , coronally positioned flap (CPF) without acellular dermal matrix allograft (ADMA). , coronally positioned flap (CPF) with acellular dermal matrix allograft (ADMA). ,0,
lidija,908,5816054,No significant difference,"Compared with 0.9% saline, neither 40 nor 120 mg of inhaled nebulized furosemide had an effect on ratings of perceived breathlessness during exercise or an effect on cardiometabolic, ventilatory, breathing pattern, or dynamic operating lung volume responses during exercise."," breathlessness, leg discomfort, chest tightness to exercise cessation were not significantly different across treatments. ", 0.9% saline , furosemide ,0,
lidija,826,4819709,Cannot tell based on the abstract,, Moving from standing to sitting without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,826,4819709,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">9Â·3</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">17Â·5</td>", Moving from standing to sitting without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,932,5462761,Cannot tell based on the abstract,, cold perception thresholds , baseline ," 2?mA anodal tDCS, when applied for 15?min over the motor cortex ",0,
lidija,932,5462761,Significantly increased,"2â??mA anodal tDCS, when applied for 15â??min over the motor cortex, induced a change only in cold perception threshold but not in the other studied parameters (one-way follow-up ANOVA for cold perception: F(2,18)â??=â??3,68; pâ??=â??0.046)).", cold perception thresholds , baseline ," 2?mA anodal tDCS, when applied for 15?min over the motor cortex ",0,
lidija,845,5062194,No significant difference,There were no between-group differences regarding the neonatal outcome., neonatal outcome ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
lidija,839,4819709,Cannot tell based on the abstract,," Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (&amp;gt;?15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work/employment, Going out socially, Sporting activity or exercise ", Ultrasound?guided foam sclerotherapy , Endovenous laser ablation ,0,
lidija,839,4819709,No significant difference,"Bending the legs without discomfort	50	2Â·7	3Â·0	0Â·94 (0Â·75, 1Â·17)
90	12Â·6	14Â·1
Lifting heavy objects without discomfort	50	5Â·9	4Â·8	1Â·11 (0Â·87, 1Â·42)
90	20Â·5	16Â·9
Moving from standing to sitting without discomfort	50	2Â·2	1Â·9	1Â·12 (0Â·90, 1Â·40)
90	10Â·4	9Â·3
Standing still for a long time (>â??15 min) without discomfort	50	4Â·8	3Â·9	1Â·14 (0Â·90, 1Â·44)
90	20Â·0	15Â·8,<td align=""left"" colspan=""1"" id=""bjs10081-ent-0450"" rowspan=""1"" valign=""top"">Participation items</td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0451"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0452"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0453"" rowspan=""1"" valign=""top""></td><td align=""center"" colspan=""1"" id=""bjs10081-ent-0454"" rowspan=""1"" valign=""top""></td>,Partial return to normal work/employment	50	6Â·3	4Â·4	1Â·17 (0Â·89, 1Â·52)
90	21Â·1	15Â·4,Going out socially	50	6Â·9	7Â·1	0Â·88 (0Â·70, 1Â·10)
90	23Â·9	25Â·8
Sporting activity or exercise	50	14Â·2	15Â·7	0Â·80 (0Â·61, 1Â·04)
90	55Â·5	62Â·6,UGFS was superior to EVLA in terms of return to full time work, looking after children and walking (both short and long distances)."," Bending the legs without discomfort, lifting heavy objects without discomfort, Moving from standing to sitting without discomfort, Standing still for a long time (&amp;gt;?15 min) without discomfort, Driving a car, Doing housework, Partial return to normal work/employment, Going out socially, Sporting activity or exercise ", Ultrasound?guided foam sclerotherapy , Endovenous laser ablation ,0,
lidija,659,2720945,Significantly increased,"Improvement of lung function, dyspnea and quality of life as multiple criteria were statistically significant relative to placebo", Quality of life , placebo , cineole ,0,
lidija,910,2774638,Significantly decreased,"As daily calcium intake increased, the 24-hour recall increasingly underreported calcium (r = 0.41, P < .001) compared with the CFFFQ.", Estimation of underreported calcium as daily calcium intake increased , 24-hour recall , calcium-focused food frequency questionnaire (CFFFQ) ,0,
lidija,946,4693888,Cannot tell based on the abstract,," Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group) ", Custodiol , Custodiol-N ,0,
lidija,946,4693888,No significant difference,"Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group) was similar in both groups."," Cardiac index, catecholamines ICU-stay and mortality (1 death in the control group) ", Custodiol , Custodiol-N ,0,
lidija,758,2847809,Significantly decreased,The primary AVF failures at two months were 21.6% in placebo group and 5.2% in clopidogrel group (P = 0.03)., The primary arteriovenous fistula failures at two months , Placebo , Clopidogrel ,0,
lidija,832,4819709,Cannot tell based on the abstract,, Doing housework , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,832,4819709,Significantly increased,"<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">7Â·3</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">15Â·7</td>", Doing housework , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,739,3446002,Significantly decreased,The duration of phototherapy was significantly shorter in clofibrate group (P<0.001)., The duration of phototherapy , control group , single dose of 50 mg/kg clofibrate ,0,
lidija,689,2899760,Significantly increased,"Fusion rate in the SR group was 92%, and in the TM group 69% (PÂ <Â 0.05).", Fusion rate , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ?¢ (TM) , raditional Smithâ??Robinson (SR) procedure with autograft  ,0,
lidija,903,4320624,Significantly increased,"All abediterol doses achieved significant improvements versus placebo in FEV1 AUC 0â??6, 0â??12, and 0â??24 h, and peak and trough FVC (pâ??<â??0.05).", peak FEV1 , placebo , Abediterol ,0,
lidija,695,2858204,Significantly increased,"In the intention-to-treat analysis, complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group (P = 0.03)."," In the intention-to-treat analysis, complete healing of the index ulcer ", placebo , hyperbaric oxygen therapy ,0,
lidija,626,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,626,3187863,Significantly increased,"The women randomised to the MU had acupuncture in 55.1% of the cases, a significantly higher rate compared with those randomised to the NU (37.9%; RR 1.45, 95% CI 1.25â??1.69) and SU (37.9%; RR 1.45, 95% CI 1.22â??1.73)", Pain relief: Acupuncture , Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,821,5294349,No significant difference,All markers designated on the radiographs could be visualized in the CT volumes., datasets of 3D coordinates , 2â??4 stereo radiograph pair examinations , CT scan ,0,
lidija,774,3221331,Cannot tell based on the abstract,, did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
lidija,774,3221331,No significant difference,"In the intervention group 7/73 respondents (9.6%) and in the control group 4/81 (4.9%) (P = .3) stated they did not attempt to quit at all,", did not attempt to quit smoking at all , set a quit date and received a general health video message sent to their phone every 2 weeks. ," an automated package of video and text messages over 6 months that was tailored to self-selected quit date, role model, and timing of messages. Extra messages were available on demand to beat cravings and address lapses. ",0,
lidija,834,4819709,Cannot tell based on the abstract,, Wearing clothes that show the legs , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,834,4819709,No significant difference,"<td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">90</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">56Â·6</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">58Â·7</td>", Wearing clothes that show the legs , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,870,5332972,Cannot tell based on the abstract,, comfortable gait speed and fast gait speed  , before repetitive facilitative exercises and orthotic treatment. , after 4 weeks of repetitive facilitative exercises and orthotic treatment. ,0,
lidija,870,5332972,Significantly increased,"comfortable gait speed increased significantly from 0.68 Â± 0.22 (m/sec) to 0.81 Â± 0.24 (m/sec) (p<0.01), and fast gait speed increased significantly from 0.80 Â± 0.28 (m/sec) to 0.96 Â± 0.31 (m/sec) (p<0.01).", comfortable gait speed and fast gait speed  , before repetitive facilitative exercises and orthotic treatment. , after 4 weeks of repetitive facilitative exercises and orthotic treatment. ,0,
lidija,743,1913177,Cannot tell based on the abstract,, Wound complications , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
lidija,743,1913177,No significant difference,Wound complications were found in 10 of 19 patients after CST and 13 of 18 patients after PR., Wound complications , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
lidija,751,3387601,Significantly increased,"There was a negative correlation between CSF protein and duration of mechanical ventilation in the PE group (p = 0.037), but not in the IVIG group (p = 0.132).", negative correlation between CSF protein and duration of mechanical ventilation , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
lidija,924,5295802,Cannot tell based on the abstract,, IFN-? and VEGF in depression patients , before intervention , after intervention ,0,
lidija,924,5295802,No significant difference,"Furthermore, depression responders had significantly less decrease in IFN-Î³ (p=0.005) and VEGF (p=0.045) levels as well.", IFN-? and VEGF in depression patients , before intervention , after intervention ,0,
lidija,949,3278655,No significant difference,MTPM values were similar in the 2 groups (p = 0.9)., maximum total point motion (MTPM) , cemented component. , The trabecular metal tibial monoblock component (TM) ,0,
lidija,947,4693888,Cannot tell based on the abstract,, peak CKMB , Custodiol , Custodiol-N ,0,
lidija,947,4693888,Significantly decreased,"peak CKMB (52 Â± 40 vs. 41 Â± 30 U/l, superiority p < 0.002) was significantly lower in the Custodiol-N group", peak CKMB , Custodiol , Custodiol-N ,0,
lidija,960,2656477,Significantly increased,<td></td><td></td><td></td><td></td><td></td><td></td>," emotional well-being quality of life, self-efficacy related to negative emotions, food availability in overweight and obese endometrial cancer survivors. ", usual care , lifestyle intervention (LI) consisting of exercise and nutritional counseling with cognitive-behavior modification ,0,
lidija,769,2361948,Significantly increased,Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3 months; P=0.016), Overall survival time , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 16?Gy/2 fr/day 1 and 8 (arm B) , palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer 20?Gy/5 fractions (fr)/5 days (arm A) ,0,
lidija,886,4804575,No significant difference,"The average TB incidence rate attributable to reinfection in the first year was estimated at 1.3/100 pyrs, compared to an observed rate of 2.2/100 pyrs (95Â % CI, 1.8â??2.7).", The average TB incidence rate attributable to reinfection in the first year , after isoniazid preventive therapy , during isoniazid preventive therapy ,0,
lidija,754,2430614,Cannot tell based on the abstract,, the parasitological and clinical failure rate at day 28 post treatment , artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD) , Artesunate+amodiaquine (AS+AQ) ,0,
lidija,754,2430614,Significantly decreased,"the parasitological and clinical failure rate at day 28 post treatment (PCF28) was lower in the AS+AQ group compared to the AL or AS+CD groups (corrected for re-infections: 6.6% vs 13.8% and 13.8% respectively, pâ??=â??0.08; uncorrected: 14.6% vs 27.6% and 28.1% respectively, pâ??=â??0.005). I", the parasitological and clinical failure rate at day 28 post treatment , artemether-lumefantrine (AL) and Artesunate+chlorproguanil-dapsone (AS+CD) , Artesunate+amodiaquine (AS+AQ) ,0,
lidija,767,2899760,No significant difference,No statistically significant difference in radiological fusion or in clinical outcome was found between the groups., Radiological fusion , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ?¢ (TM) , raditional Smithâ??Robinson (SR) procedure with autograft  ,0,
lidija,697,1852268,Invalid Prompt,, obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillinâ??tazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",1, there is no data
lidija,889,5801479,No significant difference,"Although not significant, vitamin D supplementation let to a reduction of nuclear factor kappa B (NF-kB) (p = 0.75) expression in PBMCs isolated from diabetic patients compared to the placebo group. There was no statistically significant change following supplementation with vitamin D on gene expression of interleukin (IL)-4, IL-6, and vascular endothelial growth factor (VEGF) in PBMCs of diabetic HD patients."," nuclear factor kappa B (NF-kB), interleukin (IL)-4, IL-6, and vascular endothelial growth factor (VEGF)  ", placebo (n = 30) every 2 weeks for 12 weeks ," vitamin D supplements at a dosage of 50,000 IU (n = 30) every 2 weeks for 12 weeks ",0,
lidija,819,4577567,Significantly increased,a decreased stride frequency (4.44%; p<0.0001) and internal work (7.09%; p<0.05) were found. In RWF, internal work , free stride frequency , stride frequency manipulation ,0,
lidija,664,3446002,Cannot tell based on the abstract,, side effects , control group , single dose of 50 mg/kg clofibrate ,0,
lidija,664,3446002,No significant difference,On serial daily examination during phototherapy and up to 2 days after that no problems or side effects were observed., side effects , control group , single dose of 50 mg/kg clofibrate ,0,
lidija,693,2944158,Significantly decreased,"in the routine replacement (mean, 1.8) than the clinical indication group (mean, 1.5), with significantly higher hospital costs per patient (P < 0.001).", hospital costs per patient for the course of IV therapy , routine replacement , clinically indicated ,0,
lidija,872,5209819,Significantly increased,Pre-treatment testing performed within the ADDO increased from 0 to 65% of suspected malaria patients who visited a shop (95% CI 60.8â??69.6%), The proportion of patients present at the ADDO who received a diagnostic test  ," Before trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. "," After trainings covered signs and symptoms of uncomplicated and severe malaria, stocking, use, and disposal of RDTs, and appropriate case management based on RDT results. ",0,
lidija,780,2722000,Significantly decreased,"The actuarial rebleeding rate in the prophylactic group was significantly lower than that in the ondemand group (33.9% vs. 62.1%, p=0.004).", rebleeding , received antibiotics only when infection was suspected or established , received antibiotics treatment after randomization with intravenous cefotaxime 2 gram q 8 hr for 7 days ,0,
lidija,728,1468428,No significant difference,median labour time was similar between groups (515 min. with enema v 585 min. without enema; P = 0.24), Median labour time , no enema , 1 litre saline enema ,0,
lidija,828,4819709,Significantly increased,"UGFS was superior to EVLA in terms of return to fullâ??time work (hazard ratio 1Â·43, 95 per cent c.i. 1Â·11 to 1Â·85), looking after children (1Â·45, 1Â·04 to 2Â·02) and walks of short (1Â·48, 1Â·19 to 1Â·84) and longer (1Â·32, 1Â·05 to 1Â·66) duration.", Walking short distances (&lt;?20 min ) without discomfort , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,927,4192987,No significant difference,The three different regimens were found to be similar in their ability to control 17-hydroxyprogesterone and testosterone levels., 17-hydroxy progesterone and testosterone levels , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 09.00-10.00 pm  , 10-15 mg/m2 total dose of hydrocortisone. Two-fifths of the total dose of hydrocortisone was administered in the morning and one-fifth of the total dose was administered at 06.00-07.00 pm ,0,
lidija,690,2899760,No significant difference,There was no difference in clinical outcomes between the groups., clinical outcomes , anterior cervical decompression and fusion (ACDF) with Trabecular Metalâ?¢ (TM) , raditional Smithâ??Robinson (SR) procedure with autograft  ,0,
lidija,874,5729252,Significantly increased,"Significant differences were noted for the bosentan-treated (nâ??=â??12) vs. untreated (nâ??=â??12) groups in hospital-free survival (603.44â??Â±â??50.074Â days vs. 358.87â??Â±â??68.65Â days; hazard ratio [HR], 0.19; Pâ??=â??0.017) and overall survival (671Â days vs. 433.78â??Â±â??66.98Â days; HR, 0.10; Pâ??=â??0.0082).", overall survival of patients with pulmonary hypertension (PH) secondary to idiopathic pulmonary fibrosis (IPF) , no treatment , bosentan ,0,
lidija,863,4078386,No significant difference,"We didnâ??t find any significant differences in the mean of HCV-RNA numbers between statin and placebo groups in 12th week of treatment, in the end of treatment and 6 months after treatment (P > 0.05).", mean of HCV-RNA numbers at the end of treatment  , placebo , 20 mg atorvastatin nightly for 3 months ,0,
lidija,853,5577662,No significant difference,global assessment of improvement was significantly greater with CCH 0.40Â mg and 0.60Â mg (PÂ â?¤Â 0.0014) but not statistically significant with CCH 0.25Â mg versus placebo (PÂ =Â 0.13)., global assessment of improvement ," dose of 0.25 mg, 0.40 mg, or 0.60 mg (1:1:1 ratio) and then allocated placebo (4:1 ratio) ", receive a dose of 0.25 mg (1:1:1 ratio) and then allocated to active treatment (CCH) ,0,
lidija,799,4785315,Significantly decreased,"Mother-to-infant bonding was significantly better in the intervention group for all women (MD â??0.30 (95% CI â??0.61 to â??0.00) p=0.05),", Mother-to-infant bonding , standard maternity care ," additional lay support (in this instance Pregnancy Outreach Workers, POWs) ",0,
lidija,957,4803984,Significantly increased,"<td align=""left"" colspan=""6"" rowspan=""1""><hr></td>", the frequency of Apgar score?8 in the first and 5th minutes  , control groups , supportive care or acupuncture group ,0,
lidija,964,4889691,Significantly increased,The hospital discharge rate of the patients with OHCA was significantly higher in the AutoPulse CPR group than in the Manual CPR group (18.8% vs. 6.3%; p = 0.03)., The hospital discharge rate of the patients with OHCA , manual chest compression for cardiopulmonary resuscitation (CPR) of out-of-hospital cardiac arrest (OHCA) , AutoPulse automated chest compression device ,0,
lidija,878,4088715,Cannot tell based on the abstract,, rate of intubations , standard group , CPAP + standard of care (nCPAP group) ,0,
lidija,878,4088715,Significantly decreased,"Finally, the rate of intubations was higher in the standard group (n = 8, n = 3) than the nCPAP group (P < 0.01).", rate of intubations , standard group , CPAP + standard of care (nCPAP group) ,0,
lidija,866,5680306,No significant difference,Vitamin D and placebo groups did not differ in any inflammatory markers or NFÎºB activity (all pâ??>â??0.05).," hsCRP, TNF, MCP-1, IFN-?, any of the interleukins "," the placebo group receiving an equivalent number of identical placebo capsules, which were continued daily for a period of 16 weeks "," vitamin D group receiving an initial bolus dose of 100,000 IU (in 2 capsules) followed by 4,000 IU (in 4 capsules) of cholecalciferol daily ",0,
lidija,656,2607225,Cannot tell based on the abstract,, Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
lidija,656,2607225,No significant difference,"Appetite loss decreased from 3 to 6 months (mean=5.1â??3.7, s.d.=14.2â??11.1), worsened at 12 months (mean=5.8, s.d.=16.0) and decreased again at 24 months (mean=4.1, s.d.=12.7) in GR patients, whereas it improved from 3 to 6 and 12 months (mean=8.1, 4.0, 2.4; s.d.=17.7, 12.6, 10.8) and worsened at 24 months (mean=2.8, s.d.=10.7) in non-GR patients (F=4.1, d.f.=3/963, P=0.007).", Appetite loss , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
lidija,857,5062234,Significantly decreased,The number of patients requiring intraoperative supplemental fentanyl in TAP group was 8 and in local infiltration group was 16 (P = 0.028)., intraoperative supplemental fentanyl , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
lidija,876,2974815,Significantly decreased,Significantly fewer patients in the â??phone callsâ?? group discontinued treatment compared to those in the â??no phone callsâ?? group (4 vs. 30; p<0.0094)., discontinued treatment , â??no phone callsâ?? group , phone callsâ?? group ,0,
lidija,685,2447617,No significant difference,"The mean intracranial pressure values 72 hours and 7 days after injury were lower in the progesterone group than in the placebo group, but there was no statistical significance between the two groups (P > 0.05).", The mean intracranial pressure values 72 hours and 7 days after injury , placebo , progesterone ,0,
lidija,901,4677000,Cannot tell based on the abstract,, On average (median) pain  in the paediatric population , placebo , lidocaine gel (2%) ,0,
lidija,901,4677000,Significantly decreased,On average (median) pain has been reduced by 2.0/5 (verum) versus 1.2/5 (placebo) (Table 3). Nonparametric analysis (Mann-Whitneyâ??â??U test) of treatment related difference in pain assessment yielded a statistical significance (p < 0.001), On average (median) pain  in the paediatric population , placebo , lidocaine gel (2%) ,0,
lidija,905,4320624,Significantly increased,"Abediterol produced dose-dependent improvements in peak FEV1 from baseline compared with placebo, from 0.274 (95% CI 0.221, 0.327) to 0.405 L (95% CI 0.353, 0.458) for abediterol 0.313 to 2.5 Î¼g, respectively (pâ??<â??0.0001 all doses)", Dose-dependent changes from baseline in trough FEV1 , placebo , Abediterol ,0,
lidija,775,3198285,Invalid Prompt,, lowâ??glycemic index , high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,1," LGI is a test group, not data"
lidija,802,2888205,No significant difference,"<th></th><th colspan=""6""><hr></th>", six-minute walk test , fibromyalgia (FM) education control (FME) group - received information and support ," lifestyle physical activity (LPA) - 30 minutes of self-selected moderate-intensity LPA, five to seven days per week ",0,
lidija,671,1876597,No significant difference,"Both drugs were well tolerated; serious adverse events were uncommon and unrelated to study drugs.


Conclusion:", Adverse Events , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
lidija,687,2447617,Significantly increased,"<td align=""left"">6 months</td><td></td><td></td>", The analysis using the dichotomization of GOS scores at 3 months post injury , placebo , progesterone ,0,
lidija,842,2891743,Significantly increased,"<td colspan=""4""><hr></td>", transurethral resection (TUR) syndrome , glucose 5% solution , glycine 1.5% solution as irrigating fluid ,0,
lidija,847,5062194,Cannot tell based on the abstract,, preoperative anxiety ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
lidija,847,5062194,Significantly decreased,Mothers premedicated with midazolam showed a lower level of preoperative anxiety and a higher degree of postoperative satisfaction than the control group., preoperative anxiety ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,0,
lidija,776,3198285,No significant difference,"there was no significant difference in birth weight (LGI 3.3 Â± 0.1 kg vs. HF 3.3 Â± 0.1 kg; P = 0.619), birth weight centile (LGI 52.5 Â± 4.3 vs. HF 52.2 Â± 4.0; P = 0.969), prevalence of macrosomia (LGI 2.1% vs. HF 6.7%; P = 0.157), insulin treatment (LGI 53% vs. HF 65%; P = 0.251), or adverse pregnancy outcomes."," birth weight, birth weight centile, prevalence of macrosomia, insulin treatment, adverse pregnancy outcomes ", high-fiber moderate-GI diet (HF) (target glycemic index GI ~60) , lowâ??glycemic index diet (target glycemic index [GI] ~50) ,0,
lidija,1088,4082484,Significantly increased,"On the other hand, the consumption of the curry meal increased FMD from 5.2âÂ±â2.5% to 6.6âÂ±â2.0% (Pâ=â0.001),",  flow-mediated vasodilation (FMD) , spice-free control meal , single serving of curry meal ,0,
lidija,1048,4748685,Significantly decreased,"decrease in sweets consumption (pseudo-median of the differences = â2 servings/week; p = 0.04; 95 % CI = [â4, â0.00001]) in the intervention group", Self-reported consumption of sweets , Standard care , CAPSYS system ,0,
lidija,1014,5101425,Significantly decreased,The analysis revealed that the rate of thrombocytopenia after surgery was higher in the control group (P = 0.012)., Thrombocytopenia rate , Placebo , Desmopressin ,0,
lidija,1097,4109867,Cannot tell based on the abstract,, average daily feed intake (ADFI) , basal diet , 2% seamustard ,0,
lidija,1097,4109867,Significantly decreased,significantly decreased average daily feed intake (ADFI) and increased gain:feed was found in the SW dietary group compared to control (p<0.05), average daily feed intake (ADFI) , basal diet , 2% seamustard ,0,
lidija,984,5490116,No significant difference,The intravenous dexamethasone group showed higher blood glucose levels at 24 h but was not clinically relevant, Glucometric random blood sugar at 24 hours , Ropivacaine 0.2% alone (Group A) ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
lidija,982,5490116,Cannot tell based on the abstract,, Mean visual analog scale , Ropivacaine 0.2% alone (Group A)  ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
lidija,982,5490116,Significantly decreased,"VAS scores were significantly lower in Groups B and C at 8 h, 12 h, and 24 h compared to Group A.", Mean visual analog scale , Ropivacaine 0.2% alone (Group A)  ," Ropivacaine 0.2%, and intravenous injection dexamethasone 8 mg (Group B) ",0,
lidija,1175,4821313,Significantly decreased,There was a significant increase in serum creatinine and a decrease in eGFR 48 hr post-intervention in group 1 (short regimen), eGFR  , sodium bicarbonate solution using the long regimen (initial intravenous bolus of 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 6 hr). , sodium bicarbonate solution using the short regimen (intravenous bolus 3 mL/kg/h of 166 mEq/L sodium bicarbonate for 1 hour immediately before radiocontrast) ,0,
lidija,1067,520750,Cannot tell based on the abstract,,  VAS overall pain , analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA) , A mixed-effects model repeated measures approach (MMRM) ,0,
lidija,1067,520750,Significantly decreased,"<td align=""left"" colspan=""10""><bold><underline>LOCF_ANCOVA</underline></bold></td>",  VAS overall pain , analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA) , A mixed-effects model repeated measures approach (MMRM) ,0,
lidija,1152,5626376,Significantly increased,"At 18 months, the higher improvement in total WOMAC was in HA1 with a 65.20% reduction, followed by PRP (55.01%), HA3 (49.57%), and HA2 (29.82%), whereas the control group had a 14.55% increase over baseline (p=0.001 control compared to HA1 and HA3)."," At 18 months, the higher improvement in total WOMAC ", standard care (control) , a single injection of PRP (GPSâ¢ II) ,0,
lidija,1183,5064056,Cannot tell based on the abstract,, Mean disability , no therapy ," tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice ",0,
lidija,1183,5064056,Invalid Prompt,, Mean disability , no therapy ," tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice ",1, there is no control group
lidija,989,2920262,No significant difference,"Singing did not improve single breath counting, breath hold time or shuttle walk distance.", Breath hold time , Usual care , Singing classes ,0,
lidija,1072,4821226,Cannot tell based on the abstract,, fibroblast colony forming units (CFU-Fs). , core decompression only , core decompression with the application of bone marrow aspirate concentrate ,0,
lidija,1072,4821226,Significantly increased,the number of CFU that best represents the number of MSC shows a significant increase, fibroblast colony forming units (CFU-Fs). , core decompression only , core decompression with the application of bone marrow aspirate concentrate ,0,
lidija,1196,3743641,Cannot tell based on the abstract,, improvement in the womenâs most bothersome vulvovaginal atrophy symptoms , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
lidija,1196,3743641,Significantly increased,treatment with BZA 20 mg/CE 0.625 mg resulted in a significantly greater decrease from baseline in vaginal pH (P < 0.001) and a greater improvement in the womenâs most bothersome vulvovaginal atrophy symptoms (P < 0.05) compared with placebo, improvement in the womenâs most bothersome vulvovaginal atrophy symptoms , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
lidija,1008,5003313,Significantly decreased,The symptom severity of this syndrome meaningfully changed eight weeks after intervention in the intervention group compared to the control group (P < 0.001)., Symptom severity after 8 weeks  , No exercises , Stretching exercises ,0,
lidija,1070,4821226,No significant difference,we could not perceive any significant change in the volume of FHN in both treatment groups, femoral head necrosis (FHN) , core decompression only , core decompression with the application of bone marrow aspirate concentrate ,0,
lidija,1164,4223523,Significantly increased,"A significant improvement in olanzapine-treated participants over placebo-treated participants was observed in secondary outcome measures, including sleep efficiency, total sleep time, and sleep latency.", sleep efficiency  , placebo , olanzapine ,0,
lidija,1040,4588874,Cannot tell based on the abstract,, Nicotine concentration after ad lib use , Conventional tobacco cigarette , E-cigarettes  ,0,
lidija,1040,4588874,Significantly decreased,"the nicotine concentration at the end of the ad lib use period was significantly higher following use of the tobacco cigarette compared to the e-cigarettes,", Nicotine concentration after ad lib use , Conventional tobacco cigarette , E-cigarettes  ,0,
lidija,1052,4075638,Significantly decreased,"<th colspan=""1"" rowspan=""1""></th><th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""4"" rowspan=""1""><hr></th><th align=""left"" colspan=""4"" rowspan=""1""><hr></th><th colspan=""1"" rowspan=""1""></th>", Decrease in symptoms among patients with high immature defense style after 3 years , Long-term psychotherapy , Short-term psychotherapy ,0,
lidija,1172,3224529,Significantly decreased,"There were large differences in ineffective efforts (24 Â± 23 per hour of sleep in PSV, and 0 during NAVA) and episodes of central apnea (10.5 Â± 11 in PSV vs. 0 during NAVA).", episodes of central apnea and ineffective efforts , pressure support ventilation (PSV) , neurally adjusted ventilatory assist (NAVA) ,0,
lidija,1076,1562433,Significantly increased,"<td colspan=""4""><hr></td>", vastus lateralis obliquus (VLO) EMG activity , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,0,
lidija,973,3491047,No significant difference,"No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months), and total adherence between the three groups.", Total adherence to the program , Walking intervention (W) , Walking and Behavioural intervention (WB) ,0,
lidija,978,5619630,Significantly increased,The medication-plus-exercise group showed significantly more improvement at 12 and 24 weeks than the medication-only group., Improvement in the Hamilton Rating Scale for Depression at 24 weeks , Medication only , Medication plus exercise ,0,
lidija,1124,3611646,Cannot tell based on the abstract,," names forgotten, numbers forgotten, memory impairment in recalling special events in life, forgetfulness, losing of valuables, difficulty in remembering multiple items to be purchased, inability to concentrate, impaired recognition, memory impairment of recall of previous histories, difficulty in recalling information quickly, depression, and inability to relax  ", administered Sarkaradi Granules (SG). ," administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar. ",0,
lidija,1124,3611646,Significantly decreased,"In comparison to Group B, Group A showed highly significant relief in symptoms such as names forgotten (63.56%), numbers forgotten (61.62%), and memory impairment in recalling special events in life (59.71%) at a level of P`0.001, and forgetfulness (68.60%), losing of valuables (73.64%), difficulty in remembering multiple items to be purchased (68.21%), inability to concentrate (68.14%), impaired recognition (79.7%), memory impairment of recall of previous histories (60.66%) at a level of P`0.01, and a significant relief (P`0.05) from difficulty in recalling information quickly (71.57%), depression (89.66%), and inability to relax (82.93%) [Table 3]."," names forgotten, numbers forgotten, memory impairment in recalling special events in life, forgetfulness, losing of valuables, difficulty in remembering multiple items to be purchased, inability to concentrate, impaired recognition, memory impairment of recall of previous histories, difficulty in recalling information quickly, depression, and inability to relax  ", administered Sarkaradi Granules (SG). ," administered with the Granules of Guduchyadi Medhya Rasayana (GMR), which contains Guduchi (Tinospora cordifolia Wild.), Apamarga (Achyranthes aspera Linn.), Vidanga (Embelia ribes Burm. f.), Shankhapushpi (Convolvulus pluricaulis Chois.), Vaca (Acorus calamus Linn.), Haritaki (Terminalia chebula Zetz.), Kushtha (Saussurea lappa C.B. Clarke), Shatavari (Asparagus racemosus Wild.), Cowâs ghee and sugar. ",0,
lidija,975,3798949,Significantly decreased,"the average treatment cost per patient was an excess of Â£431 for a non-commercial trial (range Â£6393 excess to Â£6005 saving) and a saving of Â£9294 for a commercial trial (range Â£0 to Â£71â480).,On an average, non-commercial trial protocols were associated with a small per patient excess treatment cost, whereas commercial trials were associated with a substantially higher cost saving.", Savings in drugs and dispensing costs , Commercial sponsored trials ," Academic, non-commercial sponsored trials ",0,
lidija,1143,3742017,Significantly increased,E-performed significantly better than C-group children on the Kaufman Assessment Battery for Children-Second Edition (KABC-II), performed on KABC-II Composite Index Simultaneous Processing and on subtest Rover ," C-group - the Newborn Intensive Care Unit (NICU) experience (exposure to bright lights, heightened sound, frequent interventions), which alters brain development. ", E-group - The Newborn Individualized Developmental Care and Assessment Program (NIDCAP) provides a system of NICU care and environmental structure that supports preterm infantsâ early brain development. ,0,
lidija,1190,3743641,Cannot tell based on the abstract,, mean daily number of moderate to severe hot flushes at week 4 , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
lidija,1190,3743641,Significantly decreased,"at week 4, BZA 20 mg/CE 0.45 mg and BZA 20 mg/CE 0.625 mg were associated with a significant decrease (P < 0.001) in the adjusted mean daily number of moderate to severe hot flushes as compared with placebo.", mean daily number of moderate to severe hot flushes at week 4 , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
lidija,1184,4653470,Cannot tell based on the abstract,, Absolute increase in performance of insulin therapy for DM. , traditional on-site learning activity , serious game called InsuOnLineÂ© ,0,
lidija,1184,4653470,Significantly increased,". Absolute increase in performance was higher in the game group (40%) than in control (34%, p=0.01).", Absolute increase in performance of insulin therapy for DM. , traditional on-site learning activity , serious game called InsuOnLineÂ© ,0,
lidija,1045,4748685,Significantly decreased,"The statistical evaluation of primary measures revealed significant decreases of systolic blood pressure (mean of the differences = â9 mmHg; p = 0.03; 95 % CI = [â17.29, â0.71]), LDL (pseudo-median of the differences = â7.9 mg/dl; p = 0.04; 95 % CI = [â18.5, â0.5])", LDL values , Standard care , CAPSYS system ,0,
lidija,1187,3971783,Significantly increased,After intervention the means of PaCO2 and RR in the control group were significantly higher than the case group (P < 0.0001), PaCO2 and Respiratory rates  , no breathing exercises  ," breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping ",0,
lidija,1163,3296686,Cannot tell based on the abstract,," serum ALT, AST, IL-8 or other inflammatory mediators ", baseline , Prednisone (40 mg/day for 4 days) ,0,
lidija,1163,3296686,Invalid Prompt,," serum ALT, AST, IL-8 or other inflammatory mediators ", baseline , Prednisone (40 mg/day for 4 days) ,1, nobody is receiving baseline
lidija,1098,4109867,Significantly increased,Dietary SW supplementation significantly (p<0.05) improved average daily gain and gain:feed ratio, gain:feed , basal diet , 2% seamustard ,0,
lidija,1026,4486943,Cannot tell based on the abstract,, Number of positive screens , Technology Enhanced Quitline-20 , Technology Enhanced Quitline-10  ,0,
lidija,1026,4486943,Significantly decreased,"There was a statistical difference in the number of positive screens between the two intervention groups, with TEQ-20 having slightly more positive screens than TEQ-10 (on average, 1.52 (SD=1.66) for TEQ-10 and 1.82 (SD=1.99) for TEQ-20, p=0.003).", Number of positive screens , Technology Enhanced Quitline-20 , Technology Enhanced Quitline-10  ,0,
lidija,1167,4223523,No significant difference,"There was no significant difference between olanzapine- and placebo-treated participants in SWM, SSP or RTI tasks."," Spatial Working Memory (SWM), Spatial Span (SSP), and Reaction Time (RTI) tasks ", placebo , olanzapine ,0,
lidija,1078,4667210,No significant difference,there was no significant difference in the appearance time of the MSG symptom complex between subjects orally administered G101 and those administered the placebo, the appearance time of the MSG symptom complex , maltodextrin (placebo) , Capsules (300 mg) containing Lactobacillus brevis G101 (1Ã1010 CFU/individual) ,0,
lidija,1071,4821226,No significant difference,Over the period of two years there was no significant difference between the head survival rate between both groups., the head survival rate , core decompression only , core decompression with the application of bone marrow aspirate concentrate ,0,
lidija,1035,4138383,Cannot tell based on the abstract,, Patients striving for recovery , Inpatient treatment , Self-referral treatment ,0,
lidija,1035,4138383,Significantly increased,"Patients in the control group expressed more resignation and passivity, giving the impression that they were stuck in these experiences.", Patients striving for recovery , Inpatient treatment , Self-referral treatment ,0,
lidija,1005,3442969,Significantly increased,"However, we found a marked difference in PFS between patients with codon 12 and 13 mutant tumors treated with infusional 5-FU versus capecitabine based regimens.", Median progression-free survival , CAPOX , FUFOX ,0,
lidija,1091,2644667,Cannot tell based on the abstract,, Mean Â± SD patient global assessment scores at the end of the SR phase , morphine , hydromorphone ,0,
lidija,1091,2644667,No significant difference,"<td colspan=""5""><hr></td>", Mean Â± SD patient global assessment scores at the end of the SR phase , morphine , hydromorphone ,0,
lidija,1050,5089605,Cannot tell based on the abstract,, ACR20/50/70 response , Placebo?plus MTX or Golimumab , Golimumab plus?MTX ,0,
lidija,1050,5089605,No significant difference,". At week 256, 72.8% of all patients had an ACR20 response, 54.6% had an ACR50 response, and 38.0% had an ACR70 response.,After the placebo crossover at week 52, ACR20 and ACR50 response rates were maintained for all treatment groups through week 256", ACR20/50/70 response , Placebo?plus MTX or Golimumab , Golimumab plus?MTX ,0,
lidija,1002,3878029,No significant difference,Smoking abstinence self-efficacy did not differ between the interventions (p =â.14) at the 2-week follow-up, Smoking abstinence after 2 weeks , Relaxation , Hypnotherapy ,0,
lidija,1185,3971783,Significantly increased,"O2sat, PaO2 in the case group were higher than the control group (P < 0.0001)."," O2sat, PaO2 ", no breathing exercises  ," breathing exercises were performed for 45 minutes, and were pursued for four weeks in the morning following and prior to sleeping ",0,
lidija,1059,3787573,No significant difference,"no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12), and aspects of WOMAC:", Western Ontario and McMaster Universities Osteoarthritis Index for pain , Exercise alone , NMES plus exercise ,0,
lidija,1123,5489138,Cannot tell based on the abstract,, confirmed disability progression , EDSS/T25FW or EDSS/9HPT , EDSS/T25FW/9HPT ,0,
lidija,1123,5489138,Significantly increased,". The 3-part combination measure (EDSS or T25FW 20% or 9HPT 20%) was associated with more 3-month CDP events (41.4% and 63.9% of patients as 12 and 24 months, respectively) than the 2-part measure (EDSS or T25FW 20% [38.5% and 59.5%, respectively]),", confirmed disability progression , EDSS/T25FW or EDSS/9HPT , EDSS/T25FW/9HPT ,0,
lidija,1006,3442969,Cannot tell based on the abstract,, Overall survival , CAPOX , FUFOX ,0,
lidija,1006,3442969,Invalid Prompt,, Overall survival , CAPOX , FUFOX ,1, We presently can not draw final conclusions regarding patient management from this study.
lidija,1188,5122238,Significantly decreased,"The investigation of the incidence of inter- and post-operative shivering in patients in the three groups revealed that within the study period, 31 patients suffered from shivering among which 9, 5, and 17 cases were in 1 mg/kg hydrocortisone group, 2 mg/kg hydrocortisone group, and placebo group, respectively, and according to the Chi-square test, the difference among the three groups was significant (P = 0.004).", incidence and intensity of shivering , received normal saline , received 1 mg/kg and 2 mg/kg hydrocortisone ,0,
lidija,1044,4748685,Significantly decreased,significant decreases of systolic blood pressure (mean of the differences = â9 mmHg; p = 0.03;, Systolic blood pressure , Standard care , CAPSYS system ,0,
lidija,1197,3743641,Cannot tell based on the abstract,, reduction in the incidence of dyspareunia , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
lidija,1197,3743641,Significantly decreased,statistically significant reduction in the incidence of dyspareunia relative to placebo during weeks 9â12 of therapy (P < 0.001), reduction in the incidence of dyspareunia , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
lidija,1039,4588874,Cannot tell based on the abstract,, Level of exhaled CO , Conventional tobacco cigarette , E-cigarettes  ,0,
lidija,1039,4588874,Significantly decreased,"use of the e-cigarettes produced no increase the exhaled CO levels, whereas the cigarette significantly increased the exhaled CO more than eight (8) times above the baseline.", Level of exhaled CO , Conventional tobacco cigarette , E-cigarettes  ,0,
lidija,1161,3296686,Cannot tell based on the abstract,," day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF ", baseline , Pioglitazone (30 mg/day for 14 days) ,0,
lidija,1161,3296686,No significant difference,"We found no statistically significant differences between day-0 and day-14 in serum IL-28B, TNF-Î±, IL-1Î±, IL-1Î², IL-6, IL-8, IL-10, IFN-Î³, MCP-1 and HGF"," day-14 in serum IL-28B, TNF-?, IL-1?, IL-1?, IL-6, IL-8, IL-10, IFN-?, MCP-1 and HGF ", baseline , Pioglitazone (30 mg/day for 14 days) ,0,
lidija,983,5490116,Significantly decreased,The mean VAS was significantly lower in the Group C for up to 24 h following the caudal block, Mean visual analog scale , Ropivacaine 0.2% alone (Group A)  , Ropivacaine 0.2% with injection dexamethasone 8 mg (Group C) ,0,
lidija,1140,3895597,No significant difference,"The VAS scores of abdominal pain at week 4, were significantly decreased in both tiropramide and octylonium groups, but the change from baseline did not differ between the 2 groups (difference,-0.26 mm; 95% CI,-4.33-3.82; P = 0.901). Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL were also improved by both treatments, and the changes from baseline did not differ."," Abdominal pain and discomfort assessed using VAS scores, diaries, and IBS-QoL ", octylonium 20 mg , tiropramide 100 ,0,
lidija,1034,4138383,Significantly increased,patients with a contract for self-referral appeared to have more confidence in strategies to cope with mental illness, Self-confidence in applying methods to deal with mental illness , Inpatient treatment , Self-referral treatment ,0,
lidija,1047,4748685,Significantly increased,statistically significant increase in self-reported fruit and vegetable consumption (pseudo-median of the differences = 5.4 servings/week; p = 0.04;, Self-reported consumption of fruits and vegetables , Standard care , CAPSYS system ,0,
lidija,972,3491047,No significant difference,"No statistical significance (p> 0.05) was observed for long-term adherence (6 to 12 months),", Long-term adherence to the program , Walking intervention (W) , Walking and Behavioural intervention (WB) ,0,
lidija,1055,2223531,No significant difference,Toxicities of oral etoposide phosphate were not different from those known for etoposide, Toxicity , Oral etoposide , Oral etoposide phosphate ,0,
lidija,1182,5064056,Cannot tell based on the abstract,, Mean pain intensity , no therapy ," tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice ",0,
lidija,1182,5064056,Invalid Prompt,, Mean pain intensity , no therapy ," tailored exercise therapy, including ultrasound-guided activation of deep muscles, strengthening and stretching exercises and advice ",1, there is no control group
lidija,1019,3159986,Significantly increased,Respiratory endurance time increased from 6.1 Â± 0.8 to 20.3 Â± 3.0 min (P < 0.001), Improvement in respiratory endurance , Baseline characteristics , Respiratory muscle endurance training ,0,
lidija,1010,5018157,Cannot tell based on the abstract,, Risk of hypotension , Low-dose bupivacaine spinal anesthesia in healthy parturients , Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients ,0,
lidija,1010,5018157,Significantly decreased,The incidence rate of hypotension in the preeclamptic patients (55.8%) was less than that of the healthy parturients (89.2%), Risk of hypotension , Low-dose bupivacaine spinal anesthesia in healthy parturients , Low-dose bupivacaine spinal anesthesia in pre-eclamptic parturients ,0,
lidija,994,3074545,Cannot tell based on the abstract,, Use of health care services , Non-mentored group , Non-professional mentor support ,0,
lidija,994,3074545,No significant difference,<td></td><td></td><td></td><td></td><td></td><td></td><td></td>, Use of health care services , Non-mentored group , Non-professional mentor support ,0,
lidija,1066,520750,Significantly increased,"<td align=""left"" colspan=""10""><bold><underline>LOCF_ANCOVA</underline></bold></td>"," HAMD17 total score, ", analysis of covariance (ANOVA or ANCOVA) with missing data imputed by the last observation carried forward approach (LOCF_ANCOVA) , A mixed-effects model repeated measures approach (MMRM) ,0,
lidija,1118,3577738,No significant difference,"did not differ in website use in comparison with the control condition; neither in terms of the number of pages visited (t(456)â=â1.44, pâ=â.15), nor in terms of time on the website (t(456)â=â0.01, pâ=â.99).", website use and terms of the number of pages visited and terms of time on the website , website without social presence elements. , website with social presence elements. ,0,
lidija,1204,4280954,Cannot tell based on the abstract,, serum TC and non-HDL-C levels  ," received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)  "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA;  ",0,
lidija,1204,4280954,Significantly decreased,Flaxseed supplementation significantly decreased serum TC and non-HDL-C levels, serum TC and non-HDL-C levels  ," received a high-fat diet (40% energy as fat), deficient in ?-linolenic acid (ALA)  "," high-fat diet enriched with ground flaxseed 15 g/100 g of food, rich in ALA;  ",0,
lidija,1119,3577738,Significantly increased,"Participants in the experimental condition focused on the social presence elements, both in terms of frequency (F(1, 98)â=â40.34, p<.001) and duration (F(1, 88)â=â39.99, p<.001)", focused on the social presence elements in terms of frequency and duration , website without social presence elements. , website with social presence elements. ,0,
lidija,1029,4221638,No significant difference,Progressive intracranial haemorrhage was present in 21 (18%) of 120 patients allocated to TXA and in 32 (27%) of 118 patients allocated to placebo. The difference was not statistically significant [RRâ=â0.65 (95% CI 0.40 to 1.05)]., Intracranial haemorrhage , Placebo , Tranexamic acid ,0,
lidija,1117,5215617,Cannot tell based on the abstract,, The median duration of exclusive breastfeeding , receive the usual health messages from the Matlab regular health staff , receive exclusive breastfeeding counselling from the counsellors ,0,
lidija,1117,5215617,Significantly increased,"The median duration of exclusive breastfeeding was longer in the breastfeeding counselling group (135 days, 95% CI: 131â139) than in usual health message group (75 days, 95% CI: 68â82) â a difference of 60 days (p < 0.001).", The median duration of exclusive breastfeeding , receive the usual health messages from the Matlab regular health staff , receive exclusive breastfeeding counselling from the counsellors ,0,
lidija,1073,1562433,Cannot tell based on the abstract,, Maximum voluntary isometric contractions , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,0,
lidija,1073,1562433,Invalid Prompt,, Maximum voluntary isometric contractions , hip abduction at 0Â° and 30Â° , knee extension at 90Â° of flexion ,1," the data are shown in figures, and there are no figures shown"
lidija,1194,3743641,Cannot tell based on the abstract,, increase from baseline in the mean proportion of intermediate cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
lidija,1194,3743641,Significantly increased,Both BZA/CE groups also showed a significantly greater reduction from baseline in the mean proportion of parabasal cells (P < 0.001) and a significantly greater increase from baseline in the mean proportion of intermediate cells (P < 0.05) compared with placebo at weeks 4 and 12., increase from baseline in the mean proportion of intermediate cells , placebo ," BZA/CE combines bazedoxifene (BZA), a selective estrogen receptor modulator, with conjugated estrogens (CE), ",0,
lidija,1043,5746685,No significant difference,There was no significant weight rebound from the start of weight loss maintenance to 12 months for either group, Attrition after 12 months , Basic weight loss maintenance program , Enhanced weight loss maintenance program ,0,
lidija,1087,4395717,Significantly decreased,pain was significantly reduced in the upper thoracic manipulation group., reduction in pain , cervical stability training (CST) , upper thoracic manipulation (UTM) ,0,
lidija,995,3074545,Cannot tell based on the abstract,, Improvements in physical and mental wellbeing , Non-mentored group , Non-professional mentor support ,0,
lidija,995,3074545,No significant difference,<td></td><td></td><td></td><td></td><td></td><td></td><td></td>, Improvements in physical and mental wellbeing , Non-mentored group , Non-professional mentor support ,0,
lidija,1023,4895766,Cannot tell based on the abstract,, Control of foul smell , Betadine ointment , Katupila Kalka with Tila Taila ,0,
lidija,1023,4895766,Significantly decreased,"foul smell was controlled after 3 days in patients of Group A. In Group B, foul smell from ulcer continues until the wound was healed.", Control of foul smell , Betadine ointment , Katupila Kalka with Tila Taila ,0,
lidija,996,3074545,No significant difference,<td></td><td></td><td></td><td></td><td></td><td></td><td></td>, Changes in total Composite Abuse Scale score , Non-mentored group , Non-professional mentor support ,0,
lidija,988,2920262,Significantly increased,the physical component score of the SF36 improved in the singers (n = 15) compared to the controls (n = 13); +7.5(14.6) vs. -3.8(8.4) p = 0.02., Improvement in SF-36 physical component score , Usual care , Singing classes ,0,
lidija,1083,5610854,Significantly increased,17 of the 38 eyes in group 1 (44.7%) required IOP-lowering medications as compared to seven of the 111 eyes in group 2 (6.3%)., intraocular pressure (IOP)-lowering medications , primary trabeculectomy group 2 , laser peripheral iridotomy (LPI) group 1 ,0,
lidija,1058,3787573,No significant difference,"no statistically significant difference was found between the NMES + Ex and the Ex groups in NRS (P = 0.52), TUG test (P = 0.12),", Timed Up and Go test , Exercise alone , NMES plus exercise ,0,
lidija,1160,3296686,Cannot tell based on the abstract,, serum IL-8 levels at day-14 , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
lidija,1160,3296686,Significantly increased,Pioglitazone increased serum IL-8 levels at day-14 when compared to baseline day-0 values (mean changeâ=ââ166.8 IU/ml; 95% CI: â300.1 to â33.5; Pâ=â0.019), serum IL-8 levels at day-14 , baseline , Pioglitazone (30 mg/day for 14 days) ,0,
lidija,1176,3752932,Significantly decreased,"<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th>,<th colspan=""1"" rowspan=""1""></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th><th align=""left"" colspan=""2"" rowspan=""1""><hr></th>", the mean number of incontinence episodes/24 h and the mean number of micturitions/24 h , placebo , mirabegron (50 and 100 mg) ,0,
lidija,1134,4627811,Significantly increased,"Training improved maximal workload, peak oxygen uptake (VO2peak) related to the predicted VO2peak", VO2peak tended , continuous training (CT) 12-weeks inpatients NYHA II-III , high-intensity interval training (HIT) for 12-weeks in patients NYHA II-III ,0,
lidija,1105,5064802,Cannot tell based on the abstract,, Hemodynamic data , no helium , Helium preconditioning (3 Ã 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp. ,0,
lidija,1105,5064802,No significant difference,"Neither the preconditioning nor the postconditioning stimulus altered hemodynamics,", Hemodynamic data , no helium , Helium preconditioning (3 Ã 5 min of 70 % helium and 30 % oxygen) was applied before aortic cross clamping; postconditioning (15 min of helium) was applied before release of the aortic cross clamp. ,0,
lidija,1171,3224529,Significantly decreased,"Proportions of REM sleep duration were different in the two ventilatory modes (4.5% (range, 3-11%) in PSV and 16.5% (range, 13-29%) during NAVA (p = 0.001)), as well as the fragmentation index, with 40 Â± 20 arousals and awakenings per hour in PSV and 16 Â± 9 during NAVA (p = 0.001)", fragmentation index , pressure support ventilation (PSV) , neurally adjusted ventilatory assist (NAVA) ,0,
lidija,1133,5225252,Cannot tell based on the abstract,, the Gag response rate , ASH group , SLA and SHA groups ,0,
lidija,1133,5225252,Significantly increased,"In the SLA and SHA groups combined, the Gag response rate was significantly higher 2 weeks after the second vaccination (95.7%), compared with the rate in the ASH group 2 weeks after either the Ad35-GRIN prime or the SeV-Gag boost (54.5% for both; P = .008).", the Gag response rate , ASH group , SLA and SHA groups ,0,
lidija,1307,5789132,Cannot tell based on the abstract,, The mean SEM score ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
lidija,1307,5789132,Significantly decreased,"The mean SEM scores in male patients receiving LA conventional and insulin syringe were 2.12 and 1.24 respectively. The difference was statistically significant (Figs 2 and 3).,The mean SEM scores in female patients receiving LA with conventional and insulin syringe were 2.59 and 1.55 respectively. The difference was statistically significant.", The mean SEM score ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
lidija,655,2607225,Cannot tell based on the abstract,, cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
lidija,655,2607225,Significantly increased,"Individual support patients had a higher level of cognitive functioning (mean=87.4, s.d.=14.2) as compared with non-IS patients (mean=84.0, s.d.=16.4) (F=4.6, d.f.=1/321, P=0.046)", cognitive functioning , standard care ," individual support, group rehabilitation and a combination of the two (Group rehabilitation) ",0,
lidija,546,2666722,Cannot tell based on the abstract,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,0,
lidija,546,2666722,Invalid Prompt,, the risk of SARS infection , health care workers without IgG against Severe acute respiratory syndrome , health care workers with IgG against Severe acute respiratory syndrome ,1, there is no data on IgG
lidija,1211,5397544,Significantly decreased,"In group I preoperative R-values significantly decreased 1 h after the introduction of the laparoscope, after the end of surgery and on the third postoperative day.", Thromboelastography R-time , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
lidija,1305,3596913,Cannot tell based on the abstract,, progression-free survival and overall survival ," receive weekly intravenous infusions of oxaliplatin 40?mg/m2, 5-FU 500 mg/m2, and leucovorin 250?mg/m2 (3 weeks on, 1 week off) "," receive FU 500 mg/m2 IV bolus weekly Ã6 weeks plus leucovorin 500?mg/m2 IV weekly for 6 weeks during each 8-week cycle plus oxaliplatin 85?mg/m2 IV on weeks 1, 3, and 5 of each 8-week (FLOX)  ",0,
lidija,1305,3596913,No significant difference,"There was no statistical significance in progression-free survival between the 2 regimens (P value by log rank test = .4619), and so was the situation in overall survival (P-value by log rank test = .5248).", progression-free survival and overall survival ," receive weekly intravenous infusions of oxaliplatin 40?mg/m2, 5-FU 500 mg/m2, and leucovorin 250?mg/m2 (3 weeks on, 1 week off) "," receive FU 500 mg/m2 IV bolus weekly Ã6 weeks plus leucovorin 500?mg/m2 IV weekly for 6 weeks during each 8-week cycle plus oxaliplatin 85?mg/m2 IV on weeks 1, 3, and 5 of each 8-week (FLOX)  ",0,
lidija,1313,5873424,Cannot tell based on the abstract,, total sleep time , placebo tablets , paracetamol/buprenorphine ,0,
lidija,1313,5873424,Significantly increased,TST improved significantly for the active treatment group compared with the placebo group, total sleep time , placebo tablets , paracetamol/buprenorphine ,0,
lidija,713,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,1222,3917123,Cannot tell based on the abstract,, Total score of fatigue , Placebo , Routine unit care  ,0,
lidija,1222,3917123,No significant difference,"in the study group, total score of fatigue and score of fatigue in emotional, cognitive, and behavioral dimensions were significantly less than in the two groups of placebo and control after intervention (P < 0.05), but there was no significant difference between the control and placebo groups (P > 0.05).", Total score of fatigue , Placebo , Routine unit care  ,0,
lidija,623,3187863,Cannot tell based on the abstract,, Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,623,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65â0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59â0.89)", Labour dystocia , Normal unit &amp; Special unit , Midwife-led unit ,0,
lidija,760,2447617,Significantly decreased,The mortality rate of the progesterone group was significantly lower than that of the placebo group at 6-month follow-up (P < 0.05)., The mortality rate , placebo , progesterone ,0,
lidija,1336,5673730,Significantly decreased,There were two intrauterine deaths and significantly higher HbA1C at term in Group-B., HbA1C , insulin 0.8-0.9 mg/kg/day in two divided doses subcutaneously (Group-B) , oral metformin 500 mg TDS (Group-A) ,0,
lidija,1295,3636800,Significantly increased,"A greater proportion of data points were completed with the native smartphone application in comparison to the SMS text-only implementation (Î² = -.25, SE=.11, P=.02),", proportion of data points , completing 6 days of assessment (four sets of questions per day) with the SMS text-only implementation , completing 6 days of assessment (four sets of questions per day) with a native smartphone application ,0,
lidija,1262,5414544,Significantly increased,"Overall, HBsAg positivity was associated with male sex (adjusted odds ratioâ=â1.54, Pâ<â0.001)", HBsAg positivity , female , male ,0,
lidija,1275,4880652,Significantly decreased,"In the fentanyl group, systolic blood pressures at 5, 10, 15, 20 minutes and diastolic blood pressure at 5 minutes and oxygen saturation at 5 minutes were significantly lower (p<0.05).", SpO2 at 5 minutes , paracetamol (20 mg/kg) and propofol , fentanyl (1 Âµg/kg) and propofol  ,0,
lidija,1212,5397544,Cannot tell based on the abstract,, Alpha-angle values , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
lidija,1212,5397544,No significant difference,There were no significant changes in Î±-angle and maximum amplitude values during or after laparoscopic fundoplication in both groups, Alpha-angle values , Low-molecular-weight heparin only before the surgery , Low-molecular-weight heparin before and after the surgery ,0,
lidija,1217,3743198,Cannot tell based on the abstract,, Postural blood pressure measurement , No standardized guidelines or educational programs , Educational program and ED protocol for syncope evaluation ,0,
lidija,1217,3743198,Significantly increased,"Postural blood pressure measurement was more frequently performed in the intervention group than the control group (97.6% vs. 87.9%, p=0.003).", Postural blood pressure measurement , No standardized guidelines or educational programs , Educational program and ED protocol for syncope evaluation ,0,
lidija,752,3387601,Cannot tell based on the abstract,, side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
lidija,752,3387601,No significant difference,There was no significant side effect attributable to any of the treatment modalities in any of the studied patients., side effects , intravenous immunoglobulin (IVIG) , plasma exchange (PE)  ,0,
lidija,1314,5873424,Significantly increased,"In the intervention group (paracetamol/buprenorphine), SE (70%â72%), SOL (32â24Â min), and EMA (50â40Â min) improved compared with the control group (SE, 70%â67%; SOL, 47â60Â min; EMA, 31â35Â min). Treatment effects were significant (PÂ <Â .01, PÂ <Â .05, and PÂ <Â .05, respectively)."," sleep efficiency (SE), sleep onset latency (SOL), early morning awakening (EMA) ", placebo tablets , paracetamol/buprenorphine ,0,
lidija,1286,4132637,No significant difference,Major bleeding rate was similar between treatment groups (13.4 vs. 12.6%; HR 1.07; 95% CI = 0.95â1.19), major bleeding , clopidogrel , ticagrelor ,0,
lidija,1258,4488484,Significantly increased,"Participants receiving the combination of the sympathetic narrative and factual information, compared to factual information alone, were more likely to support all policies: providing naloxone to friends and family members (OR: 2.0 [95% CI: 1.4 to 2.9]", providing naloxone to friends and family members of people using opioids , no-exposure control group , Several message exposures ,0,
lidija,1328,4716419,Cannot tell based on the abstract,, Death and serious infections ,  intravenous cyclophosphamide (CYC) 0.5â1?g/m2 monthly , enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months ,0,
lidija,1328,4716419,Significantly increased,"Discontinuation due to any one of the following: death, major infection, doubling of serum creatinine or loss to follow-up was found in 7 of 32 patients (21.9%) in the CYC group and 3 of 27 patients (11.1%) in the EC-MPS group.", Death and serious infections ,  intravenous cyclophosphamide (CYC) 0.5â1?g/m2 monthly , enteric-coated mycophenolate sodium (EC-MPS) 1440?mg/day for first 6?months ,0,
lidija,831,4819709,Cannot tell based on the abstract,, Driving a car , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,831,4819709,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""2"" style=""padding-left:10%"" valign=""top"">Driving a car</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">50</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">4Â·1</td><td align=""center"" colspan=""1"" rowspan=""1"" valign=""top"">7Â·0</td><td align=""center"" colspan=""1"" rowspan=""2"" valign=""top"">1Â·78 (1Â·45, 2Â·19)</td>", Driving a car , surgery , Ultrasound?guided foam sclerotherapy ,0,
lidija,1259,4488484,Significantly increased,"passing laws to protect people if they administer naloxone (OR: 1.5 [95% CI: 1.04 to 2.2]),", passing laws to protect people who administer naloxone , no-exposure control group , Several message exposures ,0,
lidija,1332,3917204,Cannot tell based on the abstract,," Probing depth (PD), Gingival recession (GR),  Clinical attachment level (CAL) ", received scaling and root planing with hand instruments , received treatment with rotary instruments ,0,
lidija,1332,3917204,No significant difference,"comparing these two groups, the results were statistically nonsignificant. Similarly, other clinical parameters like GR and CAL gave statistically nonsignificant results [Table 3]."," Probing depth (PD), Gingival recession (GR),  Clinical attachment level (CAL) ", received scaling and root planing with hand instruments , received treatment with rotary instruments ,0,
lidija,1308,5789132,Cannot tell based on the abstract,, The mean pain score and mean SEM scores in female patients ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
lidija,1308,5789132,Significantly decreased,The mean pain score in female patients using conventional syringe was 3.40 and score using insulin syringe was 1.40 (Table 3). The difference was statistically significant. The mean SEM scores in female patients receiving LA with conventional and insulin syringe were 2.59 and 1.55 respectively. The difference was statistically significant., The mean pain score and mean SEM scores in female patients ,  receive the injection with conventional syringe , receive the injection with diabetic needle ,0,
lidija,1290,4132637,Cannot tell based on the abstract,, major or minor bleeding (by TIMI criteria) , clopidogrel , ticagrelor ,0,
lidija,1290,4132637,No significant difference,"When assessed by TIMI criteria, there was no significant difference in major or minor bleeding (13.2 vs. 12.3%; HR 1.08; 95% CI = 0.97â1.21; P = 0.16).", major or minor bleeding (by TIMI criteria) , clopidogrel , ticagrelor ,0,
lidija,757,2847809,Significantly increased,First hemodialysis from newly created AVF in clopidogrel group was significantly more successful than placebo group (P = 0.008), First hemodialysis success , Placebo , Clopidogrel ,0,
lidija,1231,2694465,Significantly decreased,"Cumulative morphine consumption was reduced after 18 hours in the morphine group (control group= 20.14 and morphine group= 14.20 mg, p=0.037", Cumulative morphine consumption , general anesthesia , 400 ?g of intrathecal morphine followed by general anesthesia ,0,
lidija,1239,5228611,Cannot tell based on the abstract,, rate of any adverse events , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
lidija,1239,5228611,Significantly decreased,Participants in the E/C/F/TAF plus DRV group had a higher rate of any adverse events [92% (n = 82) vs. 78% (n = 36), rate of any adverse events , stay on their baseline regimen , elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) 150/150/200/10 mg plus DRV 800 mg (Janssen) once daily ,0,
lidija,1284,4132637,Cannot tell based on the abstract,, stroke incidence , clopidogrel , ticagrelor ,0,
lidija,1284,4132637,No significant difference,stroke incidence did not differ significantly between treatment arms (1.3 vs. 1.4%; HR 0.95; 95% CI 0.69â1.33; P = 0.79)., stroke incidence , clopidogrel , ticagrelor ,0,
lidija,1230,2694465,Significantly decreased,"The morphine group reported less pain intensity (evaluated using a visual numeric scale), especially when coughing (18 hours postoperatively: control group= 4.73 and morphine group= 1.80, p=0.001).", pain intensity , general anesthesia , 400 ?g of intrathecal morphine followed by general anesthesia ,0,
lidija,1228,5966469,Cannot tell based on the abstract,, increase of fluency in the double loops tasks , the spelling training and the reading groups , the combined and in the pure handwriting group ,0,
lidija,1228,5966469,Significantly increased,"One of the exceptions mentioned above was a marked increase of fluency in the double loops tasks observed in the combined and in the pure handwriting group from pre-test to post-test, which outperformed the spelling training and the reading groups as indicated by the significant interaction term intervention*time (F(3,171)Â =Â 2.7, pÂ <Â 0.05, Î·p2Â =Â 0.05).", increase of fluency in the double loops tasks , the spelling training and the reading groups , the combined and in the pure handwriting group ,0,
lidija,1288,4132637,Cannot tell based on the abstract,, the rate of life-threatening or fatal bleeding or the rate of intracranial bleeding , clopidogrel , ticagrelor ,0,
lidija,1288,4132637,No significant difference,"There was no significant difference in the rate of life-threatening or fatal bleeding (6.6 vs. 6.5%; HR 1.05; 95% CI = 0.90â1.22, P = 0.56), nor any significant difference in the rate of intracranial bleeding with ticagrelor compared with clopidogrel (0.3 vs. 0.2%; HR 2.01; 95% CI = 0.81â4.99; P = 0.13).", the rate of life-threatening or fatal bleeding or the rate of intracranial bleeding , clopidogrel , ticagrelor ,0,
lidija,1216,3743198,Cannot tell based on the abstract,, Rate of certain diagnosis , No standardized guidelines or educational programs , Educational program and ED protocol for syncope evaluation ,0,
lidija,1216,3743198,No significant difference,"There was an increasing trend in the rate of certain diagnosis in the intervention group, but it was not statistically significant.", Rate of certain diagnosis , No standardized guidelines or educational programs , Educational program and ED protocol for syncope evaluation ,0,
lidija,746,1876597,Significantly decreased,"Similarly, the risk of recurrent parasitemia due to possible recrudescence (adjusted by genotyping) was significantly lower for participants treated with DP than for those treated with AL after 28 d (1.9% versus 8.9%; RD 7.0%, 95% CI 2.5%â12%) and 42 d (6.9% versus 16%; RD 9.5%, 95% CI 2.8%â16%).", the risk of recurrent parasitemia due to possible recrudescence , artemether-lumefantrine , dihydroartemisinin-piperaquine  ,0,
lidija,1257,4488484,Significantly increased,"Participants receiving the combination of the sympathetic narrative and factual information, compared to factual information alone, were more likely to support all policies: providing naloxone to friends and family members (OR: 2.0 [95% CI: 1.4 to 2.9]), training first responders to use naloxone (OR: 2.0 [95% CI: 1.2 to 3.4]),", support for training first responders to use naloxone , no-exposure control group , Several message exposures ,0,
lidija,1268,3655855,Cannot tell based on the abstract,, Red cell and plasma phospholipid eicosapentaenoic acid and docosahexaenoic acid concentrations , safflower oil placebo for 4 weeks , 1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks ,0,
lidija,1268,3655855,Significantly increased,Significant increases are noted for both EPA and DHA and their combination in both samples. In the plasma the combined EPA and DHA increased about 80% and in the red blood cells the combined fatty acids increased about half as much., Red cell and plasma phospholipid eicosapentaenoic acid and docosahexaenoic acid concentrations , safflower oil placebo for 4 weeks , 1.7 g of Long chain omega-3 fatty acids from fish oils (O3) per day for 4 weeks ,0,
lidija,633,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , high Ab group ,0,
lidija,633,4106715,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32â11.20).", Prolonged abstinence from smoking rates to 12 months , placebo , high Ab group ,0,
lidija,1234,5506592,Significantly decreased,"In 2012, after the intervention, the proportion of households who purchased anti-mosquito products in the last month was significantly lower in intervention clusters (47.8%; 2503/5293) than in control clusters (53.3%; 2707/5079) (differenceÂ âÂ 0.05, 95% CIca â0.100 to â0.010)."," The mean expenditure on the products, ", baseline , education and mobilisation activities ,0,
lidija,848,5062194,Invalid Prompt,, No statistical analysis because they are in tables ," equal volume of normal saline, 30 min before spinal anesthesia ", intravenous dose of 0.035 mg/kg of midazolam ,1,"With respect to No statistical analysis because they are in tables, characterize the reported difference between patients receiving intravenous dose of 0.035 mg/kg of midazolam and those receiving equal volume of normal saline, 30 min before spinal anesthesia."
lidija,1327,3478519,Cannot tell based on the abstract,," total fat, FM%, and percentage of trunk fat ", assigned to the dietary fat components without this genotype , assigned to the dietary fat components who carried the AA genotype of FTO rs1558902 ,0,
lidija,1327,3478519,Invalid Prompt,," total fat, FM%, and percentage of trunk fat ", assigned to the dietary fat components without this genotype , assigned to the dietary fat components who carried the AA genotype of FTO rs1558902 ,1," data are in the tables, tables not shown"
lidija,1254,3172326,Significantly decreased,. The total number of pethidine injections in the first 24 hours postoperatively was 0.6 Â± 0.6 for the case group and 2.0 Â± 0.8 for the controls (P = 0.032)., The total number of pethidine injections in first 24 hours postoperatively , 0.5 mg/kg of normal saline was injected , received 0.5 mg/kg of ketamine IV 10 minutes before the surgical incision ,0,
lidija,1248,3056193,No significant difference,There was no significant difference between PB and sertraline groups on either HAM-D or MADRS at any visit., Hamilton Rating Scale for Depression (HAM-D) and the Montgomery-Asberg Rating Scale (MADRS) , sertraline hydrochloride , placeboxetine (PB) hydrochloride extended release capsules ,0,
lidija,616,5062234,Significantly decreased,he number of patients requiring intraoperative supplemental fentanyl in TAP group was 8 and in local infiltration group was 16 (P = 0.028)., intraoperative supplemental fentanyl , local anesthetic infiltration of the port site. , Transversus abdominis plane block with 0.375% ropivacaine  ,0,
lidija,1276,3585965,Cannot tell based on the abstract,, Mean (Â± standard error of the mean) plasma GLPG0259 concentrations a , multiple oral doses (20 and 50 mg once daily) of GLPG0259 , single ascending doses (1.5â150 mg)  of GLPG0259 ,0,
lidija,1276,3585965,Invalid Prompt,, Mean (Â± standard error of the mean) plasma GLPG0259 concentrations a , multiple oral doses (20 and 50 mg once daily) of GLPG0259 , single ascending doses (1.5â150 mg)  of GLPG0259 ,1, data is in the tables
lidija,1256,4864053,Cannot tell based on the abstract,, The BP of the GABA ligand , placebo (starch) ," MSD, 100 mg l?dopa plus 25 mg carbidopa ",0,
lidija,1256,4864053,Significantly decreased,"The BP of the GABA ligand decreased significantly with lâdopa in the medial prefrontal/anterior cingulate and right insula regions (by 18%, tÂ =Â â3.63 PÂ =Â 0.0054, and 18%, tÂ =Â 3.85 PÂ =Â 0039, respectively), with no significant effect in the other regions.", The BP of the GABA ligand , placebo (starch) ," MSD, 100 mg l?dopa plus 25 mg carbidopa ",0,
lidija,1323,5236513,Cannot tell based on the abstract,, lower abdominal pain/discomfort scores at week 8 , placebo , Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 ,0,
lidija,1323,5236513,Significantly decreased,"A significant difference between the Active and Placebo groups was observed in the IBS-C â¥ 2 subpopulation on abdominal pain/discomfort (P = 0.0417, diff[95%CI] = -2.096 [-4.112;-0.080]) for AUC (W0-W8", lower abdominal pain/discomfort scores at week 8 , placebo , Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 ,0,
lidija,1232,2694465,Significantly decreased,"The plasma morphine concentration was also reduced in the morphine group 24 hours after surgery (control group= 15.87 ng.mLâ1 and morphine group= 4.08 ng.mLâ1, p=0.029)", The plasma morphine concentration , general anesthesia , 400 ?g of intrathecal morphine followed by general anesthesia ,0,
lidija,744,1913177,Significantly increased,Reherniation occurred in 10 patients after CST and in 4 patients after PR, Reherniation , prosthetic repair with e-PTFE patch (PR) , components separation technique (CST) ,0,
lidija,1324,5236513,Cannot tell based on the abstract,, Bristol Stool Scale (BSS) score , placebo , Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 ,0,
lidija,1324,5236513,Significantly increased,"There was a statistically significant increase in the Bristol Stool Scale (BSS) score between W0 and W8 in the Active group (2.41 Â± 0.817 a.u. vs 3.13 Â± 1.197 a.u., P < 0.0001,", Bristol Stool Scale (BSS) score , placebo , Saccharomyces cerevisiae (S. cerevisiae) CNCM I-3856 ,0,
lidija,1246,3466198,No significant difference,There were no significant changes in Lactobacillus crispatus or Lactobacillus jensenii in either group, detectable L. crispatus or L. jensenii , hydroxyethylcellulose (HEC) placebo gel twice daily for 14 consecutive days , Acidform twice daily for 14 consecutive days ,0,
lidija,1227,3452313,Significantly increased,". For the first attack, significantly more patients receiving sumatriptan than placebo reported headache relief for attacks occurring inside (67% vs. 33%, p=0.007) and outside (79% vs. 31%, p<0.001) the menstrual period.", headache relief for attacks occurring inside and outside the menstrual period (migraine attacks) , placebo  for 2 months , sumatriptan  for 2 months ,0,
lidija,1242,3051215,Cannot tell based on the abstract,," hsCRP, and adiponectin ", placebo , anti-inflammatory agent (Diacerein treatment group) ,0,
lidija,1242,3051215,No significant difference,"several inflammatory markers including white blood cell count, hsCRP, homocysteine, fibrinogen, TNF-Î±, and adiponectin level were also measured; no differences between the two groups were evident (Table 1)."," hsCRP, and adiponectin ", placebo , anti-inflammatory agent (Diacerein treatment group) ,0,
lidija,503,2376383,Cannot tell based on the abstract,, Mucositis throughout the study period , Placebo lozenge , PTA lozenge ,0,
lidija,503,2376383,No significant difference,The mucositis according to the WHO score did not differ throughout the study period between both groups (P>0.5)., Mucositis throughout the study period , Placebo lozenge , PTA lozenge ,0,
lidija,1277,3585965,No significant difference,. Co-administration of GLPG0259 with a single dose of methotrexate 7.5 mg did not result in any change in the pharmacokinetic profiles of either GLPG0259 or methotrexate., the rate and extent of absorption of GLPG0259 , GLPG0259  , GLPG0259 and methotrexate ,0,
lidija,855,4794897,Significantly decreased,Mean change values of PYD and CTX-I were significantly lower at 3Â months after RT (pâ=â0.035 and pâ=â0.043) in Arm A, beta-isomer of carboxy-terminal telopeptide of type I collagen , passive physical therapy , resistance training dyrung radiation therapy ,0,
lidija,1251,5225191,Cannot tell based on the abstract,, GASE-generic (generic side effects) , placebo pill , amitriptyline ,0,
lidija,1251,5225191,Significantly increased,". After the acquisition phase, subjects in the experimental group reported significantly more side effects compared with baseline and evocation.", GASE-generic (generic side effects) , placebo pill , amitriptyline ,0,
lidija,634,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
lidija,634,4106715,No significant difference,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32â11.20). The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
lidija,1318,4124480,No significant difference,SGRQ was not significantly changed., Mean SGRQ scores , continuation of unsupervised habitual physical activity , 12-weeks of progressive endurance and strength training at a local health club ,0,
lidija,1218,3743198,Cannot tell based on the abstract,, Cardiac enzymes and electroencephalography testing , No standardized guidelines or educational programs , Educational program and ED protocol for syncope evaluation ,0,
lidija,1218,3743198,Significantly decreased,"the use of cardiac enzymes and electroencephalography were lower in the intervention group than the control group, respectively (42.9% vs. 56.0%, p=0.041; 2.3% vs. 8.6%, p=0.029).", Cardiac enzymes and electroencephalography testing , No standardized guidelines or educational programs , Educational program and ED protocol for syncope evaluation ,0,
lidija,1506,5850185,Significantly increased,The subjects in the bilateral TENS+TOT group showed greater improvement in paretic ankle dorsiflexion strength (Î²=1.32; P=0.032) and in the completion time for the Timed Up and Go test (Î²=â1.54; P=0.004) than those in the unilateral TENS+TOT group, TUG completion time at A2 , unilateral TENS+TOT , bilareal Transcutaneous electrical nerve stimulation (TENS) and taskÃ¢â¬?oriented training (TOT) ,0,
lidija,1490,5379843,Significantly decreased,Total toothpaste groups show 20.51% and 38.46% significantly less calculus formation than the Cavity Protection toothpaste group (P < 0.05)., calculus formation , use the Abhaibhubejhr  , use the Total toothpastes ,0,
lidija,1361,3842830,No significant difference,"ResultsThe change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (â0.99 hours, Pâ=â.003) and istradefylline 40 mg/day (â0.96 hours, Pâ=â.003) groups compared with the placebo group (â0.23 hours).", Daily OFF time , Istradefylline 40 mg , Istradefylline 20 mg ,0,
lidija,1385,3464379,No significant difference,There were no adverse events., Adverse events , Placebo , N-acetylcysteine ,0,
lidija,1469,4367028,Significantly increased,"TBG >30Â° showed a higher BIS value than TBG <30Â°. This statistically significant (P < 0.05) trend was observed at all the 30, 60, 90, and 120th min interval.", Bispectral index values , Trendelenburg (TBG) tilt &amp;lt;30ÃÂ° , Trendelenburg (TBG) tilt &amp;gt;30ÃÂ° ,0,
lidija,1519,5593173,No significant difference,"The placebo group showed higher originality than the control group both in the CFG (p<0.04, effect size = 0.5) and in the AUT (p<0.05, effect size = 0.4), but not in the Torrance test", Torrance test (TTCT) , smelled and rated an odorant , smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions  ,0,
lidija,1409,5578640,Cannot tell based on the abstract,, ESAS QoL-score after three months , untreated (control) , vitamin D 4000 IE/day ,0,
lidija,1409,5578640,No significant difference,"The mean ESAS QoL-score was 5.5 in the vitamin D group and 4.1 in the control group, i.e. the vitamin D group had lower self-assessed QoL compared to the control group. A small improvement in the ESAS QoL-score (i.e. decrease in ESAS-score) among the vitamin D treated patients was observed after one month, eliminating the difference between the two groups; -1.4 (95% CI -2.6-(-0.21) (Tables 2 and 3, Fig 2B). After three months no further significant changes in either group were seen.", ESAS QoL-score after three months , untreated (control) , vitamin D 4000 IE/day ,0,
lidija,1481,4673066,Cannot tell based on the abstract,, evaluation of the lecturers , traditional , schema-based lecture ,0,
lidija,1481,4673066,No significant difference,"Participants rated both lecturers similarly (traditional lecture: 4.98 vs schema-based lecture: 5.25, pâ=â0.114).", evaluation of the lecturers , traditional , schema-based lecture ,0,
lidija,1353,3179725,No significant difference,Patient adherence was similarly high in both groups (91% vs. 93%; p = 0.70)., Patient adherence , Sham chest wall oscillation treatment , Active chest wall oscillation treatment ,0,
lidija,1424,5330006,Cannot tell based on the abstract,, interleukin 6 levels during exercise tests , placebo group , receiving 1200 mg of cranberry extract for 6 weeks ,0,
lidija,1424,5330006,No significant difference,"Supplementation with cranberry extract did not exert a significant effect on IL-6 concentration (main effect, pâ=â0.051).Fig. 2", interleukin 6 levels during exercise tests , placebo group , receiving 1200 mg of cranberry extract for 6 weeks ,0,
lidija,1474,4222592,Cannot tell based on the abstract,, self-reported subjective feelings of satisfaction , consumed a standardized breakfast  [Control (C)avocado-free] , consumed a standardized breakfast with Avocado Included (AI) ,0,
lidija,1474,4222592,No significant difference,"It is worth noting that the five appetite sensation measurements for both the AI and AA test meals went in a favorable and similar direction, and borderline significant findings were found between the AI and C test meal in the context of increased satisfaction (Pâ=â0.07)", self-reported subjective feelings of satisfaction , consumed a standardized breakfast  [Control (C)avocado-free] , consumed a standardized breakfast with Avocado Included (AI) ,0,
lidija,1480,4673066,No significant difference,There was no significant difference in reported extraneous (pâ=â0.36) or germane (pâ=â0.42) cognitive load., extraneous or germane load , traditional , schema-based lecture ,0,
lidija,1356,3179725,No significant difference,There were no significant differences in other secondary outcomes.," Secondary outcomes including spontaneously expectorated sputum volume, and forced expired volume in 1 second ", Sham chest wall oscillation treatment , Active chest wall oscillation treatment ,0,
lidija,1472,4222592,Significantly increased,the AA test meal increased satisfaction by 26% (P=0.02, self-reported subjective feelings of satisfaction  for the AUC(0-5h) , consumed a standardized breakfast  [Control (C)avocado-free] , consumed a standardized breakfast with Avocado Added (AA) ,0,
lidija,1484,4881089,Cannot tell based on the abstract,," mean scores in work pace, influence at work, meaning of work, predictability, rewards, role conflicts and social support from supervisor  ", baseline ,  ergonomic intervention ,0,
lidija,1484,4881089,Significantly increased,"The paired t-test showed significant differences in mean scores before and after intervention in: work pace (p = 0.002), influence at work (p = 0.005), meaning of work (p = 0.001), predictability (p = 0.001), rewards (p = 0.001), role conflicts (p = 0.001) and social support from supervisor (p = 0.001)."," mean scores in work pace, influence at work, meaning of work, predictability, rewards, role conflicts and social support from supervisor  ", baseline ,  ergonomic intervention ,0,
lidija,1448,4859395,Cannot tell based on the abstract,, plaque area , atenolol , nebivolol ,0,
lidija,1448,4859395,Significantly decreased,"At followâup, the change in EEM area was â0.33Â±2.31Â mm2 (P<0.0001), in lumen areaÂ was â0.51Â±2.54Â mm2 (P<0.0001), in plaque area wasÂ 0.18Â±2.21Â mm2 (P<0.0001)", plaque area , atenolol , nebivolol ,0,
lidija,1368,5311860,Cannot tell based on the abstract,, Alert response during the first year , Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
lidija,1368,5311860,Significantly decreased,"Our intervention significantly decreased the number of responses in intervention versus control LPHAs in the first year but less in the second year of the study. In the first year, the intervention LPHAs were significantly less likely to report the findings to external agencies", Alert response during the first year , Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
lidija,1477,4222592,Significantly decreased,", the AA test meal increased satisfaction by 26% (P=0.02) and decreased the desire to eat by 40% (P=0.01) as compared to the C test meal.", desire to eat for the AUC(0-3h) , consumed a standardized breakfast  [Control (C)avocado-free] , consumed a standardized breakfast with Avocado Added (AA) ,0,
lidija,1352,5820389,No significant difference,We found no statistically significant difference between the programs in median number of sickness absence days at 6 and 12Â months follow-up., Number of absence days due to sickness at 12 months , Outpatient program , Inpatient program ,0,
lidija,1505,5850185,Cannot tell based on the abstract,, pDF strength at A1 and A2 , baseline , bilareal Transcutaneous electrical nerve stimulation (TENS) and taskÃ¢â¬?oriented training (TOT) ,0,
lidija,1505,5850185,Significantly increased,"When compared with baseline, the BiâTENS group showed improvement in the pDF strength at A1 (mean difference, 2.67; P<0.001) and at A2 (mean difference, 4.46; P<0.001).", pDF strength at A1 and A2 , baseline , bilareal Transcutaneous electrical nerve stimulation (TENS) and taskÃ¢â¬?oriented training (TOT) ,0,
lidija,1520,4107254,Cannot tell based on the abstract,, New oral anticoagulants administration , centers admitting less than 200 patients/year , centers admitting Ã¢â°Â¥ 200 patients/year ,0,
lidija,1520,4107254,Significantly decreased,"New oral anticoagulants were more frequently (214/156 vs. 5/20) used in centers admitting less than 200 patients per year, which was statistically significant (p = 0.046).", New oral anticoagulants administration , centers admitting less than 200 patients/year , centers admitting Ã¢â°Â¥ 200 patients/year ,0,
lidija,1414,4092608,Cannot tell based on the abstract,, received an additional dose of PPSB , fresh frozen plasma , prothrombin complex concentrates (PCC) ,0,
lidija,1414,4092608,Significantly decreased,. In the FFP group 16/20 (80%) patients received an additional dose of PPSB vs 6/20 (30%) in the PCC group, received an additional dose of PPSB , fresh frozen plasma , prothrombin complex concentrates (PCC) ,0,
lidija,1373,5285426,No significant difference,"In females, there was no difference between the two groups in any of the components of urological or sexual function.", Sexual function scores in females , Laparoscopic surgery , Robotic surgery ,0,
lidija,1438,5336430,Significantly increased,"CCC was significantly higher with 5-FU 0.5%/salicylic acid 10% than with vehicle [49.5% vs. 18.2%, respectively; odds ratio (OR) 3.9 (95% CI) 1.7, 8.7; PÂ =Â 0.0006].", The proportional reduction from baseline in the total number of AK lesions per patient  , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
lidija,1410,5578640,Cannot tell based on the abstract,, infections after 3 months , untreated (control) , vitamin D 4000 IE/day ,0,
lidija,1410,5578640,Significantly decreased,"After 3 months of vitamin D supplementation a statistically significant mean difference between the groups with regards to infections could be observed, with lower values in the vitamin D treated group; -26% (95% CI -41%â(-12%))", infections after 3 months , untreated (control) , vitamin D 4000 IE/day ,0,
lidija,1346,5628593,Significantly increased,"In the 30-Hz group, there was a significant increase in the maximal voluntary isometric contraction (p=0.039)", Maximal voluntary isometric contraction , 50-Hz whole-body vibration training , 30-Hz whole-body vibration training ,0,
lidija,1451,4859395,Cannot tell based on the abstract,There was a trend toward more lowâWSS segments in the nebivolol cohort (P=0.06)., Among lowÃ¢â¬? wall shear stress (WSS) segments  ÃâEEM area  , atenolol , nebivolol ,0,
lidija,1451,4859395,Significantly decreased,"Among lowâWSS segments (TableÂ 4), those treated with nebivolol demonstrated decreased ÎEEM area compared with atenolol (P=0.02),", Among lowÃ¢â¬? wall shear stress (WSS) segments  ÃâEEM area  , atenolol , nebivolol ,0,
lidija,1366,5311860,No significant difference,", no significant differences in the effective use of syndromic alerts were observed beyond year 1.", Effective use of syndromic alerts after 1 year , Pre-existing syndromic surveillance infrastructure and processes , Standardized aberrant event detection algorithm and response protocol ,0,
lidija,1447,4859395,Cannot tell based on the abstract,, plaque components and number of TCFAs per vessel , atenolol , nebivolol ,0,
lidija,1447,4859395,No significant difference,similar changes in plaque components and number of TCFAs per vessel compared with atenolol, plaque components and number of TCFAs per vessel , atenolol , nebivolol ,0,
lidija,1429,5553001,Cannot tell based on the abstract,, the Beck Depression Inventory-II (BDI-II) difference  , wait-list control condition ," Internet-based guided self-help program, including weekly support from a therapist via encrypted email ",0,
lidija,1429,5553001,Significantly decreased,"For BDI-II, a linear model provided best fit to the data (see Multimedia Appendix 2). The intervention group exhibited a significant decline over time. The control group showed no change.", the Beck Depression Inventory-II (BDI-II) difference  , wait-list control condition ," Internet-based guided self-help program, including weekly support from a therapist via encrypted email ",0,
lidija,1462,4600230,No significant difference,"During the 2 months of clinical training, participants in the intervention and control groups completed an average Â± SD of 58 Â± 41 and 63 Â± 47 scans, respectively (P = 0.67).", completed scans during the 2 months of clinical training , clinical training only , simulation-based training followed by clinical training ,0,
lidija,1418,5456350,Cannot tell based on the abstract,, The Overall subscale , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
lidija,1418,5456350,No significant difference,"<td align=""left"" colspan=""1"" rowspan=""1""><bold>Overall Subscale</bold></td><td align=""center"" colspan=""1"" rowspan=""1"">32</td><td align=""center"" colspan=""1"" rowspan=""1"">5.2 (0.6)</td><td align=""center"" colspan=""1"" rowspan=""1"">18</td><td align=""center"" colspan=""1"" rowspan=""1"">5.3 (0.5)</td><td align=""center"" colspan=""1"" rowspan=""1"">14</td><td align=""center"" colspan=""1"" rowspan=""1"">4.9 (0.7)</td><td align=""center"" colspan=""1"" rowspan=""1"">0.1133</td>", The Overall subscale , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
lidija,1524,4518214,Cannot tell based on the abstract,, overall survival (OS) in patients with  locoregionally advanced nasopharyngeal carcinoma (NPC) , radiotherapy alone , chemoradiotherapy  ,0,
lidija,1524,4518214,Significantly increased,"The true study endpoint, 5-year OS, was 62% in the RT group and 72% in the CRT group (Plog-rankâ=â0.038; Fig. 1).", overall survival (OS) in patients with  locoregionally advanced nasopharyngeal carcinoma (NPC) , radiotherapy alone , chemoradiotherapy  ,0,
lidija,1349,5628593,Cannot tell based on the abstract,, Attendance rates , 50-Hz whole-body vibration training , 30-Hz whole-body vibration training ,0,
lidija,1349,5628593,No significant difference,No significant difference existed between the two groups in the attendance rates (p=0.286)., Attendance rates , 50-Hz whole-body vibration training , 30-Hz whole-body vibration training ,0,
lidija,1350,5820389,No significant difference,We found no statistically significant difference between the programs in median number of sickness absence days at 6 and 12Â months follow-up., Number of absence days due to sickness at 6 months , Outpatient program , Inpatient program ,0,
lidija,1514,2361520,No significant difference,There was no difference in overall QoL or its individual domains between the two treatment strategies at baseline or at any subsequent time point., overall QoL , receive delayed treatment , receive immediate treatment ,0,
lidija,1417,5456350,Cannot tell based on the abstract,, scores of the DEKA Usability subscales , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
lidija,1417,5456350,No significant difference,There were no statistically significant differences in scores of the DEKA Usability subscales for participants who completed Parts A and B and those who completed only Part A (, scores of the DEKA Usability subscales , completers of in-laboratory (Part A) only , completers of in-laboratory (Part A) and home trial (Part B) ,0,
lidija,1502,2627861,Significantly decreased,"Adjusting for baseline lead level, age, trimester of pregnancy, and dietary energy and calcium intake, calcium was associated with an average 11% reduction (0.4 Î¼g/dL) in blood lead level relative to placebo (p = 0.004).", maternal blood lead concentrations in the second/third trimester , ingest placebo ," ingest 1,200 mg dietary calcium ",0,
lidija,1517,5593173,Cannot tell based on the abstract,, Fluency and flexibility , smelled and rated an odorant , smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions  ,0,
lidija,1517,5593173,No significant difference,"We find that flexibility in the CFG was not statistically different between the placebo and control groups (MW U = 1005, p = 0.96).,In the CFG, we defined fluency as the number of shapes selected to the gallery during exploitation phases, finding no significant difference between control and placebo (MW U = 970, p = 0.73).", Fluency and flexibility , smelled and rated an odorant , smelled and rated an odorant and were told that the odorant increases creativity and reduces inhibitions  ,0,
lidija,1403,5766333,Significantly decreased,"The maintenance dose of PF was lower in the Combination group than in the PF group (2âmg/kg/h vs. 5âmg/kg/h, P â<â0.001),", The maintenance dose of PF , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
lidija,1363,4365564,No significant difference,"The rate of major neurological complications was similar between the 2 groups (investigational = 4.4%, control = 4.0%).", Major neurological complications , ALIF with BAK cages , CharitÃÂ© artificial disc ,0,
lidija,1463,2837815,No significant difference,The mean distal translation observed was â0.15Â mm for SmartSetÂ HV and â0.16Â mm for PalacosÂ R. The mean rotation around the longitudinal axis was 0.9Â° for SmartSetÂ HV and 1.2Â° for PalacosÂ R., rotations or translations , Palacos R acrylic bone cements (without antibiotics) , SmartSet HV acrylic bone cements (without antibiotics) ,0,
lidija,1464,2837815,No significant difference,The mean distal translation observed was â0.15Â mm for SmartSetÂ HV and â0.16Â mm for PalacosÂ R, The mean distal translation , Palacos R acrylic bone cements (without antibiotics) , SmartSet HV acrylic bone cements (without antibiotics) ,0,
lidija,1400,5766333,Cannot tell based on the abstract,, incidence of hypoxemia , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
lidija,1400,5766333,No significant difference,", there were no significant differences in the incidence of hypoxemia", incidence of hypoxemia , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
lidija,1449,4859395,Significantly increased,LowâWSS regions were associated with greater plaque progression (P<0.0001) and constrictive remodeling (P=0.04);, constrictive remodeling , atenolol , nebivolol ,0,
lidija,1413,4092608,Cannot tell based on the abstract,, patients reached the target INR in the first hour after ending cardiopulmonary bypass (CPB) , fresh frozen plasma , prothrombin complex concentrates (PCC) ,0,
lidija,1413,4092608,Significantly increased,"More patients in this group reached the target INR in the first hour after ending CPB (T7, P < 0.007).", patients reached the target INR in the first hour after ending cardiopulmonary bypass (CPB) , fresh frozen plasma , prothrombin complex concentrates (PCC) ,0,
lidija,1431,5566825,Significantly increased,. Results of immunity (episodes of infections or allergy related conditions) showed more than 2 times protection from immunity related illness in CP Group as compared to the control., episodes of infection/allergy related to immunity , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
lidija,1442,5336430,Significantly increased,"<td align=""left"" colspan=""4"">Treatment</td>", Treatment-emergent adverse events , vehicle , 5-fluorouracil (5-FU) 0.5%/salicylic acid 10% ,0,
lidija,1387,3464379,Cannot tell based on the abstract,, Plasma PAI-1 , Placebo , N-acetylcysteine ,0,
lidija,1387,3464379,No significant difference,There was no significant effect of NAC or placebo on plasma PAI-1 antigen or activity at either 2Â h after the first dose or after 7Â days of oral dosing (pâ>â0.05)., Plasma PAI-1 , Placebo , N-acetylcysteine ,0,
lidija,1504,5850185,Cannot tell based on the abstract,, pDF strength at A1 and A2 , unilateral TENS+TOT , bilareal Transcutaneous electrical nerve stimulation (TENS) and taskÃ¢â¬?oriented training (TOT) ,0,
lidija,1504,5850185,Significantly increased,"BiâTENS group had greater improvement than the UniâTENS group in the pDF strength at A1 (mean difference, 2.62; P=0.036) and at A2 (mean difference, 3.23; P=0.034).", pDF strength at A1 and A2 , unilateral TENS+TOT , bilareal Transcutaneous electrical nerve stimulation (TENS) and taskÃ¢â¬?oriented training (TOT) ,0,
lidija,1454,3406743,Significantly increased,A higher percentage (67%) of the enhanced intervention group was in the action/maintenance stage for vigorous physical activity at follow-up compared with baseline (47%)., engaging in vigorous physical activity , baseline , enhanced intervention (EIG) ,0,
lidija,1402,5766333,Significantly increased,"The incidence of bradycardia (defined as a pulse rate â¤â45âbpm) in the Combination group was higher than that in the PF group (37.9â% vs. 10.3â%, P â=â0.029).", the incidence of bradycardia , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
lidija,1432,5566825,Cannot tell based on the abstract,, absent due to infection/allergy/immunity related illnesses , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
lidija,1432,5566825,Significantly decreased,"There were a total of 281 participants who were absent due to infection/allergy/immunity related illnesses. Of these, 93 participants (33.09%) were in CP group while 188 (66.90%) were in the control group. This difference was found to be statistically significant (P < 0.001", absent due to infection/allergy/immunity related illnesses , cup of milk only twice a day while continuing with their normal/routine diet. , receive orally daily either CyavanaprÃ?Ãâºa (CP) (approx. 6 g) followed by a cup of milk (100 Ã¢â¬â 200 ml) ,0,
lidija,1398,5766333,Cannot tell based on the abstract,, The percentage of patients who showed restlessness  , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
lidija,1398,5766333,No significant difference,"The percentage of patients who showed restlessness was lower in the Combination group than in the PF group; however, there was no statistically significant difference between the two groups (6.9â% vs. 24.1â%, P â=â0.144).", The percentage of patients who showed restlessness  , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
lidija,1360,3842830,Cannot tell based on the abstract,, Secondary efficacy variables , Placebo , Istradefylline 20 mg or 40 mg ,0,
lidija,1360,3842830,No significant difference,No differences were observed among the groups for other secondary efficacy variables., Secondary efficacy variables , Placebo , Istradefylline 20 mg or 40 mg ,0,
lidija,1423,5330006,Cannot tell based on the abstract,, Values of total antioxidant capacity (TAC) , placebo group , receiving 1200 mg of cranberry extract for 6 weeks ,0,
lidija,1423,5330006,Significantly increased,"Compared to the controls, cranberry-supplemented athletes presented with significantly higher levels of TAC at rest and following a 24-h recovery.", Values of total antioxidant capacity (TAC) , placebo group , receiving 1200 mg of cranberry extract for 6 weeks ,0,
lidija,1465,2837815,Cannot tell based on the abstract,The mean rotation around the longitudinal axis was 0.9Â° for SmartSetÂ HV and 1.2Â° for PalacosÂ R., The mean rotation around the longitudinal axis , Palacos R acrylic bone cements (without antibiotics) , SmartSet HV acrylic bone cements (without antibiotics) ,0,
lidija,1465,2837815,No significant difference,The mean rotation around the longitudinal axis was 0.9Â° for SmartSetÂ HV and 1.2Â° for PalacosÂ R., The mean rotation around the longitudinal axis , Palacos R acrylic bone cements (without antibiotics) , SmartSet HV acrylic bone cements (without antibiotics) ,0,
lidija,1500,3846239,Cannot tell based on the abstract,," At 24 h post surgery, VAS pain scores ", bupivacaine  , bupivacaine plus dexamethasone  ,0,
lidija,1500,3846239,No significant difference,there was no statistically significant difference between the groups in VAS at 24 h after surgery P=0.221," At 24 h post surgery, VAS pain scores ", bupivacaine  , bupivacaine plus dexamethasone  ,0,
lidija,1476,4222592,Significantly decreased,"Compared to the AI meal, the AUC(0-3h) for blood insulin was higher in the C and AA meals (P=0.04 and P=0.05, respectively).", the AUC(0-3h) for blood insulin , consumed a standardized breakfast with Avocado Added (AA) or consumed a standardized breakfast  [Control (C)avocado-free] , consumed a standardized breakfast with Avocado Included (AI) ,0,
lidija,1391,4599543,Cannot tell based on the abstract,, levels of fibrinogen , received saline solution (placebo) , received fibrinogen concentrate ,0,
lidija,1391,4599543,Significantly increased,"patients in the treatment arm had significantly higher levels of fibrinogen,", levels of fibrinogen , received saline solution (placebo) , received fibrinogen concentrate ,0,
lidija,1404,5766333,Significantly decreased,"the number of rescue PF injections was fewer in the Combination group than in the PF group (2 times vs. 6 times, P â<â0.001)", the number of times a rescue PF injection , PF alone (PF group) , combination of propofol (PF) and dexmedetomidine (DEX) (Combination group) ,0,
